AP507A - Novel insecticidal 2,4-diaminoquinazolines. - Google Patents

Novel insecticidal 2,4-diaminoquinazolines. Download PDF

Info

Publication number
AP507A
AP507A APAP/P/1996/000796A AP9600796A AP507A AP 507 A AP507 A AP 507A AP 9600796 A AP9600796 A AP 9600796A AP 507 A AP507 A AP 507A
Authority
AP
ARIPO
Prior art keywords
grams
mole
compound
phenyl
diamino
Prior art date
Application number
APAP/P/1996/000796A
Other versions
AP9600796A0 (en
Inventor
11 Robert Neil HENRIE
Clinton Joseph Peake
Thomas Gerard Cullen
Albert C Lew
Munirathnam Krishnappa Chaguturu
Partha Sarathi Ray
Original Assignee
Fmc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Corp filed Critical Fmc Corp
Publication of AP9600796A0 publication Critical patent/AP9600796A0/en
Application granted granted Critical
Publication of AP507A publication Critical patent/AP507A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/541,3-Diazines; Hydrogenated 1,3-diazines
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N55/00Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dentistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Novel quinazolines having the structure

Description

NOVEL INSECTICIDAL 2.4-DIAMINQQUINAZOLINES
This invention relates to novel quinazoline compounds which are useful for controlling insects in agricultural crops. Still more particularly, this invention relates to certain 2,4-diaminoquinazoline compounds which may be used as insecticides against a variety of insects, including larvae, such as the tobacco budworm.
In accordance with the present invention it has been found that these substituted 2,4-diaminoquinazolines, and agriculturally acceptable salts thereof, when present in insecticidally effective amounts, and with a suitable agricultural carrier, are useful as active ingredients in insecticidal compositions and methods for using the same. These novel compounds, as illustrated by Compounds 43-45, 47-74,106-138,142-173, and 176-182 of Table 1 below, include the following quinazolines, which may be prepared by methods that are provided in detail in the preparative Examples 1-3, 5, and 16-19:
AP/P/ 9 4/ 0 0 7 9 6 wherein
R' is hydrogen or lower alkyl;
R2 is hydrogen, lower alkyl, lower alkylcarbonyl [e.g., -C(=O)CH, or -C(=O)C(CH,)J, 25 or lower alkoxycarbonyl [e.g., -C(=O)OC(CHJJ; or R1 and R2, taken together, form the group -R’-O-R5, wherein R5 is lower alkylene;
R* is hydrogen;
R7 is hydrogen, lower alkylcarbonlyl [e.g., -C(=O)CH,, or -C(=O)C(CH,)J, or lower alkoxycarbonyl [e.g., -C(=O)OC(CH,)];
W is selected from hydrogen, halogen, lower alkyl, lower haioalkyl, phenyl, and phenyl substituted with lower alkyl or lower haioalkyl, with the proviso that when X is phenyl, W is other than hydrogen;
Y and Z are selected from hydrogen, halogen, and phenyl; and X is selected from (a) phenyl;
BAD ORIGINAL (b) substituted aryl, [e.g., phenyl] i.e., aryl substituted with one or more of halogens (e.g., Cl, F), lower alkyl (e.g., -CH3), lower haloalkyl (e.g., -CF3), lower alkoxy (e.g., -OCH3), lower alkylthio (e.g., -SC4H9), lower alkylsulfonyl (e.g., -SO2C2H5, or -SO2C4H9), formyl, lower alkoxycarbonyl [e.g., -C(=O)OCH3], phenyl or phenyl substituted with one or more halogens (e.g., Cl, F) or lower haloalkyl (e.g., -CF3), phenoxy, or phenoxy substituted with one or more halogens (e.g., Cl, F), lower haloalkoxy, lower alkoxyalkyl, carboxy, cyano, nitro, aminocarbonyl, lower alkylcarbonylamino, lower alkylsulfonylamino;
or substituted phenyl of the formula
(X) wherein R3 is hydrogen; alkyl, (e.g. methyl, n-pentyl, or undecyl); tri(lower alkyl)silylalkyl; (4-halophenyl)lower alkyl; pentahalophenylalkyl; pyridin-2-ylalkyl; or 2-(4-alkylsulfonylphenoxy)alkyl;
(c) naphthyl;
(d) thienyl or thienyl substituted with halogen, lower alkyl, or haloalkyl;
(e) aroyl or substituted aroyi of the formula;
wherein V, W*. X’, Y’, and Z* are independently selected from hydrogen, halogen, haloalkyl, cyano, carboxy, lower aikoxycarbonyl, and phenyl substituted with halogen or haloalkyl;
(XI) (f) (aryl)(halo)alkenyl of the formula;
AP. Ο Ο 5 Ο 7
(ΧΠ) wherein V, W”, X, Y, and Z are independently selected from hydrogen, halogen, lower alkyl, lower haloalkyi, cyano, carboxy, lower alkoxycarbonyl, and aminocarbonyl;
and (g) 2,3-dihydro-2,2-dimethylbenzofuran-4-yl; 2,3-dihydro-2,2dimethylbenzofuran-7-yl; 6-halo-2,3-dihydro-2,2-dimethylbenzofuran-4-yl; 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-yl; or 2,3-dihydro-2,2-dimethyl-3-benzofuranon-4-yl.
Preferred amongst the above novel quinazolines are those of Formula IX wherein R1, R2, R6. R7. Y and Z are hydrogen; W is methyl; and X is (i) phenyl substituted with one or more of fluoro, chloro, or trifluoromethyl; (ii)
AP/P/ 9 4 / 0 0 7 9 6
where V, W”, X”, Y”, and Z” are independently selected from hydrogen, trifluoromethyl, or 2,3-dihydro-2-2,dimethylbenzofuran-4-yl; 2,3-dihydro2,2-dimethylbenzofuran-7-yl; 6-halo-2,3-dihydro-2,2-dimethylbenzofuran4-yl; 5-halO’2,3-dihydro-2,2-dimethylbenzofuran-7-yl; or 2,3-dihydro-2,2dimethyl-3-benzofuranon-4-yl.
BAD ORIGINAL A
Each of the above novel substituted phenyl quinazoline compounds 0£I S£ falling within the scope of Formula (I) are preferred because of their high insecticidal activity, and may be used in controlling insects by applying to the locus where control is desired an insecticidal amount of these compounds admixed in a suitable agricultural carrier. When thus applied to insect-infected crops such as cotton, vegetables, fruits or other crops, these compounds are highly effective against an array of insects, particularly those shown in the tables below.
0 For the purposes of this invention, as regards the above substituent groups, the following definitions apply:
The term alkyl, alone or as part of a larger moiety, includes straight or branched chained alkyl groups of 1 to 14 carbon atoms, preferably lower straight or branched alkyl of 1 to 6 carbon atoms; while halogen includes
5 chlorine, bromine, fluorine and iodine atoms. The terms haloalkyl and haloalkoxy include straight or branched chain alkyl of 1 to 14 carbon atoms, preferably lower straight or branched alkyl of 1 to 6 carbon atoms, wherein one or more hydrogen atoms have been replaced with halogen atoms, as, for example, trifluoromethyl and 2,2,2-trifluoroethoxy,
0 respectively. The terms lower alkoxy and lower dialkylamino include those moieties having 1 to 6 carbon atoms, e.g., ethoxy and N.N-dimethylamino, respectively.
The terms aryl and substituted aryl include phenyl and naphthyl, preferably phenyl or substituted phenyl, while the terms aroyl and
5 substituted aroyl include benzoyl and naphthoyl, preferably benzoyl or substituted benzoyl.
The term ’substituted as described above, when applied to the substituted aryl, aroyl, and thienyl moieties of W, X, Y, and Z in formula I, above, includes such substituents as lower alkyl, halogen, lower haloalkyl,
0 lower alkoxy, lower haloalkoxy, lower alkoxyalkyl, carboxy, lower alkoxycarbonyl, cyano, nitro, aminocarbonyl, lower alkylsulfonyl, lower alkylcarbonylamino, lower alkylsulfonylamino. lower alkylthio, lower alkylsulfonyl, formyl, lower alkoxycarbonyl, phenyl, phenyl substituted with one or more halogens or lower haloalkyl, phenoxy, phenoxy substituted
5 with one or more halogens, arylalkoxy, arylalkoxy substituted with halogen
AP.oo 50 7 or lower alkyl, aryloxyalkoxy, aryloxyalkoxy substituted with -SO2 lower alkyl or lower alkyl, or dialkylsilylalkoxy.
Groups other than aryl, aroyl, and thienyl which may also be substituted include arylalkylamino or arylaminoalkyl (where the aryl groups may be substituted with e.g., lower alkoxy or carboxyalkoxy); arylalkylimino (where the aryl group may be substituted with, e.g., lower alkoxy); arylalkycarbonylamino (where the aryl group may be substituted with, e.g. halogen); (aryl)(alkyl)aminoalkyl (where the aryl group may be substituted with, e.g. dicarboxyalkylaminocarbonyl); and (aryl)(halo)alkenyl (where the
0 aryl group may be substituted with halogen, lower alkyl, lower haloalkyl, cyano, carboxy, lower alkoxycarbonyl, or aminocarbonyl).
Illustrations of the substituted phenyl groups further include such moieties as:
OR3
halo wherein R3 is hydrogen; alkyl,( e.g. methyl, n-pentyl, or undecyl); tri(lower alky,)sily,alkyl; (4-halophenyl)lower alkyl;
pentahalophenylalkyl; pyridin-2-ylalkyl; or 2-(4-aikylsulfonylphenoxy)alkyl, or the like.
In addition, the term arylalkyl includes 2-(naphth-2-yl)ethyl; arylalkenyl includes 2-(naphth-2-yl)ethenyl; arylthio includes 3,4-dichlorophenylthio
5 and naphth-2-ylthio; arylsulfinyl includes 3,4-dichlorophenylsulfinyl and naphth-2-ylsulfinyl; while ary,sulfonyl includes 3,4-dichlorophenylsulfonyl and naphth-2-ylsulfonyl.
Synthesis of The Compounds
0 The compounds employed as insecticides in accordance with this invention are generally known to those skilled in the art, including commercial preparations thereof, or may readily be prepared from these
AP/P/ 9 4 / 0 0 7 9 6 ο
©
5 compounds by known methods. These and other methods are described in further detail in the description and examples below.
Thus, in general, the majority of the quinazoline products (formula I above) can be prepared by the cyclization of the appropriately substituted 2-aminobenzonitrile with chloroformamidine hydrochloride in diglyme, as taught by Harris et al, [J. Med. Chem., 33. 434-444 (1990)] and as further shown in Step 1 of Example 1, below. The starting 2-aminobenzonitriles are also generally available commercially, but may be prepared in accordance with the processes taught in each of Examples 2, 6, and 20-26. In these examples, the desired 2-aminobenzonitrile starting materials substituted with halogen may be prepared by the reaction of either 2aminobenzonitrile, 2-amino-5-chlorobenzonitrile, or 2-amino-6chlorobenzonitrile with 1 or 2 equivalents of N-bromosuccinimide or 1 equivalent of N-chlorosuccinimide in Ν,Ν-dimethylformamide.
Intermediates prepared by this method include the following benzonitriles:
Ο 20
Ο wherein, alternatively,
X and Z are Br;
X is Br;
X is Cl, and Z is Br;
X and Z are Cl;
W is Cl, and X is Br;
Xis Br, and Z is Cl; or W is Cl, and X and Z are Br;
with the proviso that unless otherwise specified, W, X, Y, and Z are hydrogen.
The halogenated 2-aminobenzonitrile intermediates thus prepared may then be either reacted to prepare the quinazolines (I) as previously c
©
C
Ο
C 20 ©
C 20
Ο
AP . Ο Ο 5 Ο 7 described, or used to prepare other substituted 2-aminobenzonitrile intermediates, as described below.
For example, 2-amino-5-bromo-6-chlorobenzonitrile, or 2-amino3,5-dibromobenzonitrile, can be further reacted with 1 or 2 equivalents of an optionally substituted-phenylboronic acid in the presence of tetrakis(triphenylphosphine)palladium(0) in aqueous sodium carbonate and toluene to form more complex substituted 2-aminobenzonitrile intermediates (B), as listed below. Substituted 2-aminobenzonitrile intermediates (B) prepared in this manner include, for example, 2-amino-6chloro-5-(5-chloro-2-methoxyphenyl)benzonitrile and 2-amino-6-chloro-5(3,5-dichlorophenyl)benzonitrile. These optionally substitutedphenylboronic acid intermediates are commercially available, or may be prepared by the method of Thompson and Gaudino [JOC., 49. 5237-5243 (1984)]. Step D of Example 1, Steps B-D of Example 2, and Step A of Example 5 provide detailed descriptions of how these reactions may be conducted.
Intermediates prepared by this foregoing method include those of the formula:
AP/P/ 94/00796 wherein Y is hydrogen and W, X and Z are as defined in the following table:
X z
H Phenyl Phenyl
H Phenyl H
H a Pbenyl
H Phenyl a
a Phenyl H
a Phenyl Phenyl
X. LJ
Π
a H
a a H
a XL, XC H
a H
a LAzH, /*1 H
u XU V u
Π H χΓ CP. Π H
a χΓ CF, vr3 H
χΓ j χΓ H
cf3 CF,
a 00 H
Alternatively, 2-aminobenzonrtrile intermediates substituted with alkyl may be prepared by the method of Harris et al., J. Med. Chem., 33.
AP.00507
434-444 (1990) by the transfer hydrogenation of the alkyl-substituted 2nitrobenzonitrile in the presence of 10% palladium on carbon in cyclohexene and ethanol, yielding the corresponding alkyl-substituted 2aminobenzonitrile, for example 6-methyl-2-aminobenzonitrile. The thus5 prepared 6-methyl-2-aminobenzonitrile may then be brominated with Nbromosuccinimide in Ν,Ν-dimethylformamide, yielding 2-amino-5-bromo-6methylbenzonitrile, which in turn can be reacted with 1 equivalent of a substituted-phenylboronic acid, as described above, affording the corresponding 2-amino-5-(substituted-phenyl)-6-methylbenzonitrile, for
0 example, 2-amino-5-(3,5-di(trifluoromethyl)phenyl]-6-methylbenzonitrile. Steps B-D of Example 1 provide detailed descriptions of how these intermediates may be prepared.
Intermediates prepared by these latter methods include those having the formula:
wherein Y and Z are hydrogen, and W and X are as follows:
AP/P/ 9 4/ 0 0 7 9 6
-CH3 cf3
-CH3 'O-CtCHjb
-CH3 XT’
-CH3 vCH5 ch3
-CH3 Phenyl
Other intermediates, and quinazoline products falling within formula (I) above may then be prepared from the foregoing or similar compounds by known methods.
For example, the 2-aminobenzonitrile intermediate, 2-amino-5-(2phenylethyl)benzonitrile, may be prepared using the method of Taylor and Ray [JOC., 52. 3997-4000 (1987)], by the palladium-catalyzed coupling of 2-amino-5-bromobenzonitrile with phenylacetylene, yielding 2-amino-5-(21 0 phenylethynyljbenzonitrile. The thus-prepared ethynyl compound can then be hydrogenated in the presence of 10% palladium on carbon, yielding 2amino-5-(2-phenylethyl)benzonitrile. Steps B and C of Example 6 provide a detailed description of how these reactions are conducted.
Other 2-aminobenzonitrile intermediates substituted with a sulfur1 5 bridging moiety, for example, naphth-2-ylthio, may be prepared by the method of Ashton and Hynes [J. Med. Chem., 16. 1233-1237 (1973)] by the alkylation of an appropriate arylthiol with a halogenated 2nitrobenzonitrile in the presence of potassium carbonate, yielding for example 2-nitro-5-(naphth-2-ylthio)benzonitrile. Reduction of the nitro
0 group with stannous chloride dihydrate affords the corresponding 2aminobenzonitrile intermediates. Examples 7 and 9 provide detailed descriptions of how these reactions are conducted.
A number of the quinazolines (I), or modifications thereof, may be further reacted to obtain other quinazoline derivatives falling within the
5 scope of formula I above. For example, 2,4,6-triamino-5-methylquinazoline is prepared in a step-wise manner by the nitration of 2-chloro6-methylbenzonitrile, yielding the corresponding 2-chloro-6-methyl-5nitrobenzonitrile. The 5-nitro compound may in turn be cyciyzed with guanidine carbonate in 2-ethoxyethanoi, affording 2,4-diamino-5-methyl-63 0 nftroquinazoline. These two steps of the synthesis are described in detail in Example 12. The 6-nitroquinazoline can be reduced to the corresponding 2,4,6-triamino-5-methyiquinazoline by hydrogenation in the presence of 10% palladium on carbon. Example 13 describes in detail this step in the reaction sequence.
5 In a similar manner 2,4,6-triaminoquinazoline and 2,4.6-triamino-5chloroquinazoline can be prepared. This is accomplished by the nitration
AP. Ο Ο 5 Ο 7 of, for example 2,4-diamino-5-chloroquinazoline (above) with 90% nitric acid and sulfuric acid, yielding the corresponding 2,4-diamino-5-chloro-6nitroquinazoline. The 6-nitroquinazoline is in turn reduced by either hydrogenation in the presence of 10% palladium on carbon or by treatment with stannous chloride dihydrate, affording the corresponding 2,4,6-triaminoquinazoline. Steps A and B of Example 15 describe in detail these two steps in the reaction sequence.
The 2,4,6-triaminoquinazoline derivatives described above may then optionally be treated with 2N hydrochloric acid, sodium nitrite,
0 potassium cyanide, and copper(ll) sulfate pentahydrate in water, affording C the corresponding 2,4-diamino-6-cyanoquinazoline, for example, 2,4diamino-6-cyano-5-methylquinazoline. Step A of Example 14 describes in C detail this step in the reaction sequence.
The above 2,4-diamino-6-cyanoquinazoline intermediates may be 1 5 further reacted with a substituted aniline, for example, 3,4,5-trimethoxyaniline, and hydrogen in the presence of Raney nickel in water and acetic acid, affording the corresponding 2,4-diamino-6-(substitutedaminomethyl)quinazolines. Step B of Example 14 describes in detail the preparation of this class of compounds.
In a similar manner, 2,4,6-triamino-5-chloroquinazoline can be reacted with 3,4,5-trimethoxybenzaldehyde and hydrogen in the presence of Raney nickel in 2-ethoxyethanol, affording the-corresponding 2,4¢- diamino-6-[(3,4,5-trimethoxyphenylmethyl)imino]quinazoline. Step C of
Example 15 describes in detail the preparation of this compound. In a
Q 2 5 similar manner there may also be prepared 2,4-diamino-6-(substitutedaminomethyl)quinazolines.
A series of quinazoline analogs may be prepared from the above
2,4-diamino-5-chloro-6-(5-chloro-2-methoxyphenyl)quinazoline. This is accomplished by the reaction of 2,4-diamino-5-chloro-6-(5-chloro-23 0 methoxyphenyQquinazoline with 1M boron tribromide in methylene chloride, yielding the corresponding 2,4-diamino-5-chloro-6-(5-chloro-2hydroxyphenyl)quinazoline. The hydroxy intermediate in turn is reacted with a halogen-containing compound and potassium carbonate in Ν,Νdimethylformamide, affording the appropriately 6-(5-chloro-2-substituted3 5 phenyl)quinazoline, for example, 2,4-diamino-5-chloro-6-[5-chloro-212
Ο e
©
Ο ο 25 (pyridin-2-ylmethoxy)phenyl]quinazoline. Example 3 describes in detail the preparation of this compound.
Other like analogs of quinazoline may be prepared in a similar manner. Quinazoline derivatives containing a sulphur bridge, for example those whose preparations are taught in Examples 7 and 9, can be oxidized to the corresponding sulfinyl derivatives using the method of Oae et al., [Bull. Chem. Soc. Japan, 39, 364-366 (1966)], by the treatment of, for example, with the bromine complex of 1,4-diazabicydo(2,2,2)-octane in aqueous 70% acetic acid. Example 11 describes in detail the preparation of 2,4-diamino-6-(3,4-dichlorophenylsulfinyl)quinazoline. The corresponding sulfonyl derivatives may then be prepared by treatment of these sulfur bridged quinazolines with potassium permanganate in acetic acid and water. Examples 8 and 10 describe in detail the preparation of these compounds.
Compounds of formula (I) above, wherein X is aroyl or substituted aroyl, e.g. Compounds 149-173 of Table 1, may be prepared in a step-wise manner using methods known from the open literature. Using the method of Beletskaya et al., (Bumagin et. al., Dokl. Akad. Nauh SSSR, 320(3), 619622 (1991)) an appropriately substituted aryl iodide, for example, 2-amino5-iodo-6-methylbenzonitrile, may be carbonylated under about one atmosphere of pressure with carbon monoxide and tetramethyiammonium tetra(optionally-substituted-phenyl)borate in the presence of a catalytic amount of palladium acetate, yielding the corresponding ketone, for example, 2-amino-5-(4-trifluoromethylphenylcarbonyl)-6-methytbenzonitrile. The ketone may then be cyclized with chloroformamidine hydrochloride in diglyme, a method previously described, affording the targeted quinazoline derivative, for example, 2,4-diamino-5-methyl-6-(4trifluoromethylphenylcarbonyl)quinazoline. Example 19, discusses in detail this reaction sequence.
Compounds where X is arylalkylcarbonylamino, e.g.. Compounds 174 and 175 of Table 1, may be prepared, by the reaction of a 2,4,6triaminoquinazoline, for example, 2,4,6-triamino-5-chloroquinazoline (Compound 24) with an appropriate arylalkylcarbonyl halide under basic conditions, or they may be obtained commercially from Dr. John B. Hynes, Dept. of Pharmaceutical Sciences, Medical University of South Carolina,
171 Ashley Avenue, Charleston, South Carolina 29425-2303.
AP. Ο Ο 5 Ο 7
EXAMPLES
The following examples, which disclose the preparation of representative compounds of this invention (Table 1), are for the purpose of illustrating known methods for the preparation of the compounds employed in the methods and formulations of this invention, including certain novel quinazoline compounds oer se (Compounds 43-45, 47-74, 106-138, 142173, and 176-222 ).
EXAMPLE 1
0 SYNTHESIS OF 2.4-DIAMINO-5-METHYL-6(3,5-DI(TRIFLUOROMETHYL)PHENYL]QUINAZOLINE (COMPOUND 63)
Step A Synthesis of chloroformamidine hydrochloride as an 15 intermediate
Diethyl ether, 600 mL, was cooled in an ice-bath and saturated with about 50 grams of hydrogen chloride gas. With vigorous stirring, a solution of 26.4 grams (0.628 mole) of cyanamide in 500 mL of diethyl ether was
0 added during a 15 minute period. Upon completion of addition, the icebath was removed and the reaction mixture was allowed to stir for about 15 minutes. A i«hite, solid precipitate was collected by filtration and washed q with diethyl ether. The solid was dried under reduced pressure, yielding
50.3 grams of chloroformamidine hydrochloride.
C 25
Step B Synthesis of 2-amino-6-methylbenzonitri,e as an intermediate
A stirred solution of 13.8 grams (0.085 mole) of 2-methyl-6-nitrobenzonitrile, 28 mL of cyclohexene, and 1.5 gram of 10% palladium on
0 charcoal in 280 mL of ethanol was heated at reflux for about 3 hours. After this time, the reaction mixture was filtered to remove the catalyst. The filtrate was concentrated under reduced pressure to a solid residue. The solid was triturated with 50 mL of methylene chloride, and the insoluble material was collected by filtration. Upon standing, crystals formed in the
5 filtrate. The crystals were collected by filtration and were washed quickly with a minimum amount of methylene chloride. An NMR spectrum of the
AP/P/ 9 4 / 0 0 7 9 6 c
€ o' © 25 crystals, 2.3 grams, mp 125-126°C, indicated that they were sought-after product. A second crop of product, 1.8 grams, was collected from the methylene chloride-filtrate combination. The insoluble material from the trituration was dissolved in methylene chloride and methanol and passed through a pad of diatomaceous earth. The filtrate was concentrated under reduced pressure, yielding 4.5 grams of solid. The NMR spectrum of the solid indicated that it too was the sought-after product. The total yield of 2amino-6-methylbenzonitrile was about 8.6 grams.
Step C Synthesis of 2-amino-5-bromo-6-methylbenzonitrile as an intermediate
A stirred solution of 8.3 grams (0.063 mole) of 2-amino-6-methylbenzonitrile in 125 mL of N.N-dimethyiformamide was cooled in an ice bath, and a solution of 11.2 grams (0.063 mole) of N-bromosuccinimide in 125 mL of Ν,Ν-dimethylformamide was added dropwise during a 30 minute period, while maintaining the reaction mixture temperature at about 1525°C. Upon completion of addition, the reaction mixture was stirred at ambient temperature for about 20 hours. After this time, the reaction mixture was poured into 1 liter of aqueous 3N sodium hydroxide. The mixture was then diluted to a volume of about 1700 mL with distilled water. A solid precipitate was collected by filtration and dried under reduced pressure, yielding 12.3 grams of 2-amino-5-bromo-6-methylbenzonitrile, mp 111-113°C. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of 2-amino-6-methyl-5-[3,5-di(trifluoromethyl)phenyl]benzonrtrile as an intermediate
A stirred solution of 1.7 grams (0.008 mole) of 2-amino-5-bromo-6methylbenzonitrile, 3.2 grams (0.012 mole) of 3,5-di(trifluoromethyl)phenylboronic acid, 4.3 grams (0.031 mole) of potassium carbonate and 0.3 mL of tetrakis(triphenylphosphine)paJladium(0) in 150 mL of toluene was heated at 90°C for about 20 hours. After this time, the reaction mixture was stirred with 100 mL of water, and the organic layer was separated.
The organic layer was concentrated under reduced pressure to a residue.
AP · θ θ 5 Ο 7
The residue was subjected to column chromatography on silica gel, using 30/65/5 and 20/60/20 methylene chloride / petroleum ether / ethyl acetate as eluants. The product-containing fractions were combined and concentrated under reduced pressure, yielding about 1.0 gram of 2-amino5 6-methyl-5-[3,5-di(trifluoromethyf)phenyl]benzonitrile. The NMR spectrum was consistent with the proposed structure.
Step E Synthesis of 2,4-diamino-6-methyl-5-[3,5-di(trifluoromethly)phenyljquinazoline (Compound 63)
A stirred mixture of 0.9 gram (0.003 mole) of 2-amino-6-methyl-5(3,5-di(trifluoromethyl)phenyl]benzonitrile and 0.3 gram (0.003 mole) of chloroformamidine hydrochloride (prepared in Step A of this Example) in 11 mL of diglyme was gradually warmed to 165°C during a 1.5 hour period
5 The heterogeneous mixture was maintained at 165°C for about 4.5 hours.
After this time, the reaction mixture was cooled and diluted with 200 mL of diethyl ether. The resultant precipitate, which was the hydrochloride salt of the sought-after product, was collected by filtration. The hydrochloride salt was recrystallized from n-propanol and water. The solid was converted to
0 the free base by cooling it in an ice-water bath and stirring it with 30 mL of concentrated ammonium hydroxide during a one hour period. The resultant solid was collected by filtration, yielding 0.4 gram of 2,4-diamino6-methyl-5-[3,5-di(trifluoromethyl)phenyl]quinazoline. mp 222-225°C. The NMR spectrum was consistent with the proposed structure.
NOTE: The compound of Example 1 was prepared by the method of Harris et al, {J. Med. Chem., 23,434-444 (1990)]
EXAMPLE 2
0 SYNTHESIS OF 2,4-DIAMINO-5-CHLORO-6-(5-CHLORO-2METHOXYPHENYL)QUINAZOLINE (COMPOUND 66)
Step A Synthesis of 2-amino-5-bromo-6-chlorobenzonitrile as an 3 5 intermediate
C
Q o
o 25
This compound was prepared in a manner analogous to that of Step C of Example 1, using 18.0 grams (0.010 mole) of N-bromosuccinimide, and 15.2 grams (0.010 mole) of 2-amino-6-chlorobenzonitrile in 200 mL of Ν,Ν-dimethylformamide. The yield of 2-amino-5-bromo-6-chlorobenzonitrile was 22.5 grams. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 3-bromo-4-methoxychlorobenzene as an intermediate
A rapidly stirred solution of 15.5 grams (0.074 mole) of 2-bromo-4chlorophenol, 20.0 grams (0.145 mole) of anhydrous powdered potassium carbonate, and 10 mL (0.106 mole) of dimethyl sulfate in 150 mL of acetone was heated at reflux for about 18 hours. After this time, the reaction mixture was concentrated under reduced pressure to a residue. The residue was partitioned between 100 mL each of water and methylene chloride. The organic layer was removed and washed with an aqueous solution saturated with sodium chloride. The organic layer was then dried with magnesium sulfate and filtered. The filtrate was passed through a short column of silica gel. Elution was accomplished with 500 mL of methylene chloride. The eluate was concentrated under reduced pressure, yielding 16.3 grams of 3-bromo-4-methoxychlorobenzene. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 5-chloro-2-methoxyphenylboronic add as an intermediate
A stirred solution of 5.8 grams (0.026 mole) of 3-bromo-4methoxychlorobenzene in 150 mL of tetrahydrofuran was cooled to -80°C, and 11.5 mL of n-butyllithium in hexanes (2.5 Molar - 0.029 mole) was added dropwise during a 15 minute period, while maintaining the reaction mixture temperature at about -70°C. The initial reaction was very exothermic, which required cooling the reaction mixture to about -100°C. Upon completion of the addition, the reaction mixture was stirred at -80°C for 15 minutes. After this time, 17.5 mL (0.076 mole) triisopropyl borate was added during a 1 minute period. The reaction mixture was then allowed to
AP .0 0 5 0 7
7 warm slowly to ambient temperature during a 3 hour period, where it was stirred for an additional 1 hour. After this time, the reaction mixture was concentrated under reduced pressure to a volume of about 50 mL. The concentrate was then poured into 500 mL of ice-water. The mixture was then made acidic with about 26 mL of aqueous 2N hydrochloric acid. The mixture was then filtered to collect a solid, which was dried, yielding 3.9 grams of 5-chloro-2-methoxyphenylboronic acid. The NMR spectrum was consistent with the proposed structure.
C
Ο • / c
ο 25
NOTE: A modification of the method of Thompson and Gaudino was used to prepare 5-chloro-2-methoxyphenylboronic acid, as shown above in Step C. [JOC., 43, 5237-5243 (1984)]
Step D Synthesis of 2-amino-6-chloro-5-(5-chloro-2-methoxyphenyf)benzonitrile as an intermediate
A stirred mixture of 5.7 grams (0.020 mole) of 5-chloro-2-methoxyphenylboronic acid, 3.3 grams (0.014 mole) of 2-amino-5-bromo-6-chlorobenzonitrile (prepared in Step A of this Example), 21 mL of aqueous 2M sodium carbonate, and 0.15 gram (catalyst) of tetrakis(triphenylphosphine)palladium(O) in 50 mL of toluene was heated at reflux for about 17 hours. After this time, 50 mL of ethyl acetate was added to the reaction mixture.
The organic layer was separated and washed with 50 mL of water and then with 50 mL of an aqueous solution saturated with sodium chloride. The organic layer was then dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 3.8 grams of 2-amino-6-chloro-5-(5-chloro-2-methoxyphenyl)benzonitrile. The NMR spectrum was consistent with the proposed structure.
Step E Synthesis of 2,4-diamino-5-chloro-6-(5-chloro-2-methoxyphenyl)quinazoline (Compound 66)
AP/P/ 94/00796 ,8
This compound was prepared in a manner analogous to that of Step E of Example 1, using 3.8 grams (0.013 mole) of 2-amino-6-chloro-5-(5chloro-2-methoxyphenyl)benzonitrile and 1.8 grams (0.016 mole) of chloroformamidine hydrochloride in 13 mL of diglyme. The yield of 2,45 diamino-5-chloro-6-(5-chloro-2-methoxyphenyl)quinazoline was 2.8 grams. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 3
SYNTHESIS OF 2,4-DIAMINO-5-CHLORO-6-[5-CHLORO-2-(PYRIDIN-210 YLMETHOXYJPHENYLJQUINAZOLINE (COMPOUND 73) c
Step A Synthesis of 2,4-diamino-5-chloro-6-(5-chloro-2-hydroxyphenyl)quinazoline (Compound 65) as an intermediate
A solution of 2.8 grams (0.084 mole) of 2,4-diamino-5-chloro-6-(5chloro-2-methoxyphenyl)quinazoline (prepared in Example 2) in 300 mL of methylene chloride was stirred, and 35 mL of 1.0M boron tribromide in methylene chloride was added. Upon completion of addition, the reaction
0 mixture was stirred at ambient temperature for about 21 hours. Thin layer chromatographic analysis of the reaction mixture indicated that the reaction was not complete. The reaction mixture was heated at reflux for about 6
C hours, then it was allowed to cool to ambient temperature where it was stirred for about 60 hours. After this time, the reaction mixture was poured c 2 5 into 500 mL of ice containing 100 mL of concentrated ammonium hydroxide. The mixture was filtered to collect a solid. The solid was washed with water and dried at 70°C under reduced pressure, yielding 2.4 grams of 2,4-diamino-5-chloro-6-(5-chloro-2-hydroxyphenyl)quinazoline. The NMR spectrum was consistent with the proposed structure
Step B Synthesis of 2,4-diamino-5-chloro-6-[5-chloro-2-(pyridin-2-ylmethoxy)phenyl]quinazoline (Compound 73)
Under a nitrogen atmosphere, a stirred solution of 0.5 gram (0.002
5 mole) of 2,4-diamino-5-chloro-6-(5-chloro-2-hydroxyphenyl)quinazoline,
0.3 gram (0.002 mole) of pyridin-2-ylmethyl chloride hydrochloride, and 0.5
AP. Ο Ο 5 Ο 7 gram (0.004 mole) of potassium carbonate in 5 mL of Ν,Ν-dimethylformamide was heated at 60°C for about 24 hours. After this time, the reaction mixture was concentrated under reduced pressure to a residue. The residue was taken up in 100 mL of water and was stirred for about 2 hours. The resultant solid was collected by filtration, yielding 0.6 gram of
2,4-diamino-5-chloro-6-[5-chloro-2-(pyridin-2-ylmethoxy)phenyl]quinazoline. The NMR spectrum was consistent with the proposed structure.
ς 10 EXAMPLE 4
SYNTHESIS OF 2.4-DIAMINO-6-BROMO-5-CHLOROQUINAZOLINE
Q. (COMPOUND 20)
This compound was prepared in a manner analogous to that of Step 15 E of Example 1, using 2.4 grams (0.010 mole) of 2-amino-5-bromo-6chlorobenzonitrile (prepared as in Step A of Example 2) and 1.4 grams (0.012 mole) of chloroformamidine hydrochloride in 10 mL of diglyme. The yield of 2,4-diamino-6-bromo-5-chloroquinazoline was 2.4 grams. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 5
SYNTHESIS OF 2.4-DIAMINO-5-0HLORb-6-(3,5, DICHLOROPHENYLJQUINAZOLINE (COMPOUND 51)
O 25
Step A Synthesis of 2-amino-6-chloro-5-(3.5-dichlorophenyl)benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step 3 0 D of Example 1, using 2.3 grams (0.010 mole) of 2-amino-5-bromo-6chlorobenzonitrile (prepared as in Step A of Example 2), 2.9 grams (0.015 mole) of 3,5-dichlorophenylboronic acid, 0.1 gram (catalyst) of tetrakis(triphenylphosphine)palladium(0). and 30 mL of aqueous 2M sodium carbonate in 75 mL of toluene. The solid product was '
5 recrystallized from toluene, yielding 1.9 grams of 2-amino-6-chloro-5-(3,596/90 /V6 'd/dV 10 <
c
Ο 25 dichlorophenyl)benzonitrile. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2,4-diamino-5-chloro-6-(3,5-dichlorophenyl)quinazoline (Compound 51)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 1.5 grams (0.005 mole) of 2-amino-6-chloro-5-(3,5dichlorophenyl)benzonitrile and 0.7 gram (0.006 mole) of chloroformamidine hydrochloride in 10 mL of diglyme. The solid was recrystallized from methanol, yielding 0.5 gram of 2,4-diamino-5-chloro-6-(3,5-dichlorophenyl)quinazoiine. The NMR spectrum was consistent with the proposed structure; however, methanol was present in the sample.
EXAMPLE 6
SYNTHESIS OF 2,4-DIAMINO-6-(2-PHENYLETHYL)QUINAZOLINE (COMPOUND 79)
Step A Synthesis of 2-amino-5-bromobenzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step C of Example 1, using 6.0 grams (0.051 mole) of 2-amihobenzonitrile and 9.0 grams (0.051 mole) of N-bromosucdnimide in 75 mL of N.N-dimethylformamide. The yield of 2-amino-5-bromobenzonitrile was 8.6 grams. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-5-(2-phenylethynyl)benzonitriie as an intermediate
A solution of 3.00 grams (0.015 mole) of 2-amino-5-bromobenzonitrile and 2.3 mL (0.021 mole) of phenyfacetylene in 50 mL of acetonitrile was stirred, and 10.6 mL of triethylamine, 0.13 gram of copper iodide, and 0.29 gram of bis(triphenylphosphine)palladium(ll) chloride were added in order. Upon completion of addition, the reaction mixture was stirred at ambient temperature for about 20 hours. After this time, thin layer chromatographic (TLC) analysis of the reaction mixture indicated that no
AP . Ο Ο 5 Ο 7 reaction had taken place. The reaction mixture was warmed to 70°C, where it was stirred for about 7.5 hours. An additional 0.38 gram of phenylacetylene was added, and the reaction mixture was warmed to reflux temperature where it was stirred during about an additional 16.5 hour period. After this time, TLC analysis of the reaction mixture indicated that it contained about a 1 to 1 mixture of starting bromobenzonitrile and product. An additional 5.0 mL of triethylamine and 0.09 gram of bis(triphenylphosphine)palladium(ll) chloride catalyst was added to the reaction mixture, and the heating at reflux was continued during an
0 additional 24 hour period. After this time, the reaction mixture was concentrated under reduced pressure to a residue. The residue was dissolved in ethyl acetate, and the solution was washed with 50 mL of
O aqueous, dilute hydrochloric acid. The organic layer was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using 15/10/75 tetrahydrofuran / methylene chloride / petroleum ether. The product-containing fractions were combined and concentrated under reduced pressure, yielding 0.85 gram of 2-amino-5-(2-phenylethynyl)benzonitrile. The NMR
0 spectrum was consistent with the proposed structure.
NOTE: The method of Taylor and Ray was used to prepare 2-amino-5-(2phenylethynyl)benzonitrile, as shown above in Step B.
[JOC., 52, 3997-4000 (1987)]
Step C Synthesis of 2-amino-5-(2-phenylethyl)benzonitrile as an intermediate
A solution of 0.85 gram (0.004 mole) of 2-amino-5-(2-phenyl3 0 ethynyl)benzonitrile in 150 mL of ethanol was prepared, and 0.2 gram (catalyst) of 10% palladium on carbon was added. The mixture was then hydrogenated using a Parr hydrogenator. Upon completion of the uptake of the theoretical amount of hydrogen, the reaction mixture was filtered and concentrated under reduced pressure to a residue. The residue was dried
5 under reduced pressure, yielding 0.74 gram of 2-amino-5-(2-phenylethyl)AP/P/ 94/00796 benzonitrile. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of 2,4-diamino-6-(2-phenylethyl)quinazoline 5 (Compound 79)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 0.74 gram (0.003 mole) of 2-amino-5-(2-phenylethyl)benzonitrile and 0.41 gram (0.004 mole) of chloroformamidine
0 hydrochloride in 11 mL of diglyme. The yield of 2,4-diamino-6-(2phenylethyl)quinazoline was 0.66 gram, mp 178-180°C, si. decomp. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 7
5 SYNTHESIS OF 2,4-DIAMINO-6-(NAPHTH-2-YLTHIO)QUINAZOLINE (COMPOUND 88)
Step A Synthesis of 2-nitro-5-(naphth-2-ylthio)benzonitrile as an intermediate
A stirred solution of 10.0 grams (0.055 mole) of 5-chloro-2nitrobenzonitrile and 8.8 grams (0.055 mole) of 2-naphthalenethiol in 80 mL of N.N-dimethylformamide was cooled to 0°C, and 7.6 grams (0.055 mole) of potassium carbonate was added. Upon completion of addition,
5 the reaction mixture was stirred at 0°C for 1 hour. Thin layer chromatographic (TLC) analysis of the reaction mixture after this time indicated that the reaction had not gone to completion. The reaction mixture was then allowed to warm to ambient temperature, where it was stirred for about 18 hours. The reaction mixture was stirred with 80 mL of pyridine and then
0 was diluted with water until a solid precipitate formed. The solid was collected by filtration and was washed in turn with an aqueous solution of 10% pyridine, water, an aqueous solution of 1% hydrochloric acid, and finally with water. The solid was then dissolved in ethyl acetate and dried with magnesium sulfate. The mixture was filtered, and the filtrate was
5 concentrated under reduced pressure to a residual solid. The solid was subjected to column chromatography on silica gel. Elution was
AP . 0 0 5 0 7 r
C c
O 25 accomplished with 10% ethyl acetate in heptane. The product-containing fractions were combined and concentrated under reduced pressure, yielding 13.5 grams of 2-nitro-5-(naphth-2-ylthio)benzonitrile. A small sample was recrystallized from ethyl acetate / hexane, mp 139-140°C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-5-(naphth-2-ylthio)benzonitrile as an intermediate
A stirred solution of 13.0 grams (0.042 mole) of 2-nitro-5-(naphth-2ylthio)benzonitrile in 200 mL of diglyme was cooled to 0°C, and a solution of 30.3 grams (0.134 mole) of stannous chloride dihydrate in 91 mL of concentrated hydrochloric acid was added. Upon completion of addition, the reaction mixture was allowed to warm to ambient temperature, where it was stirred during a 2 hour period. After this time, the reaction mixture was poured, with stirring, into a mixture of 260 grams of aqueous 50% potassium hydroxide in 300 grams of ice. An oily material, which dropped out of the solution, ultimately solidified. The solid was collected by filtration and was washed with water. The solid was dissolved in methylene chloride and was dried with magnesium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure, yielding 12.0 grams of 2-amino-5-(naphth-2-ylthio)benzonitrile. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2,4-diamino-6-(naphth-2-ylthio)quinazoline (Compound 88)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 12.0 grams (0.043 mole) of 2-amino-5-(naphth-2ylthio)benzonitrile and 5.5 grams (0.048 mole) of chloroformamidine hydrochloride in 25 mL of diglyme. The yield of 2,4-diamino-6-(naphth-2ylthio)quinazoline was 12.7 grams. The NMR spectrum was consistent with the proposed structure.
NOTE: The compound of Example 7 was prepared by the method of Ashton and Hynes. [J. Med. Chem., 1233-1237 (1973)]
AP/P/ 9 4/ 0 0 7 9 6
EXAMPLE 8
SYNTHESIS OF 2,4-DIAMINO-6-(NAPHTH-2-YLSULFONYL)QUINAZOLINE (COMPOUND 90)
A solution of 2.0 grams (0.006 mole) of 2,4-diamino-6-(naphth-2ylthio)quinazoline (prepared in Example 7) in 80 mL of acetic acid was stirred, and a solution of 2.0 grams (0.013 mole) of potassium
0 permanganate in 75 mL of water was added dropwise during a 1 hour C . period. Upon completion of addition, the reaction mixture was stirred at ambient temperature for about 18 hours. After this time, the reaction mixture was filtered through diatomaceous earth. The filtrate was made basic by adding an excess amount of concentrated ammonium hydroxide.
5 The resultant precipitate was collected by filtration and was washed in turn with water, methanol, and acetone. The precipitate was stirred in hot Ν,Νdimethylformamide and treated with decolorizing carbon. The mixture was filtered hot, and the filtrate was set aside. The residue collected by the filtration was again stirred with hot Ν,Ν-dimethylformamide and filtered.
0 The two filtrates were combined and poured into 500 grams of ice. The resultant solid was collected by filtration, yielding 0.9 gram of 2,4-diamino6-{naphth-2-ylsulfonyl)quinazoline, mp 300-302°C. The NMR spectrum * was consistent with the proposed structure, i
5 EXAMPLE 9
O SYNTHESIS OF 2,4-DIAMINO-6-(3,4DICHLOROPHENYLTHIO)QUINAZOLINE (COMPOUND 80)
0 Step A Synthesis of 2-nitro-5-(3,4-dichlorophenylthio)benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step A of Example 7, using 10.1 grams (0.006 mole) of 5-chloro-2-nitrobenzo3 5 nitrile, 9.9 grams (0.006 mole) of 3,4-dichlorobenzenethiol, 7.7 grams (0.006 mole) of potassium carbonate in 80 mL of Ν,Ν-dimethylformamide.
AP. Ο Ο 5 Ο 7
The yield oi 2-nitro-5-(3,4-dichlorophenylthio)benzonitrile was 15.9 grams, mp 136-138°C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-5-(3,4-dichlorophenylthio)benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step B of Example 7, using 15.9 grams (0.049 mole) of 2-nitro-5-(3,4-dichloro1 0 phenylthio)benzonitrile, 34.6 grams (0.153 mole) of stannous chloride dihydrate, and 100 mL of concentrated hydrochloric acid in 245 mL of diglyme. The yield of 2-amino-5-(3,4-dichlorophenylthio)benzonitrile was ( 15.2 grams, mp 126-128°C. The NMR spectrum was consistent with the proposed structure.
5
Step C Synthesis of 2,4-diamino-6-(3,4-dichlorophenylthio)quinazoline (Compound 80)
This compound was prepared in a manner analogous to that of Step
E of Example 1, using 14.7 grams (0.050 mole) of 2-amino-5-(2,4-dichlorophenylthio)benzonitrile and 6.3 grams (0.055 mole) of chloroformamidine hydrochloride in 30 mL of diglyme. The yield of 2,4-diamino-6-(3,4-dichlorophenylthio)quinazoline was 12.2 grams, mp 232-234°C. The NMR spectrum was consistent with the proposed structure.
c 25 v EXAMPLE 10
SYNTHESIS OF 2,4-DIAMINO-6-(3,4-DICHLOROPHENYLSULFONYLJQUINAZOLINE (COMPOUND 82)
This compound was prepared in a manner analogous to that of Example 8, using 2.0 grams (0.006 mole) of 2,4-diamino-6-(3,4-dichlorophenylthio)quinazoline and 1.9 grams (0.012 mole) of potassium permanganate in 60 mL of acetic acid and 75 mL of water. The yield of 2,43 5 diamino-6-(3,4-dichlorophenylsulfonyl)quinazoline was 0.6 gram, mp 286289°C. The NMR spectrum was consistent with the proposed structure.
AP/P/ 94/00796
EXAMPLE 11
SYNTHESIS OF 2,4-DIAMINO-5-(3,4-DICHLOROPHENYLSULFINYL)QUINAZOLINE (COMPOUND 81)
Step A Synthesis of the bromine complex of 1,4-diazabicyclo(2,2,2)octane as an intermediate
0 A stirred solution of 2.2 grams (0.02 mole) of 1,4-diazabicyclo< (2,2,2)octane in 10 mL of carbon tetrachloride was warmed to 40°C, and a solution of 3.2 grams (0.02 mole) of bromine in 15 mL of carbon Q tetrachloride was added dropwise. The resultant precipitate was collected by filtration, washed with carbon tetrachloride, and air-dried, yielding 5.0
5 grams of the bromine complex of 1,4-diazabicyclo(2,2,2)octane.
NOTE: The method of Oae et al. was used to prepare the bromine complex of 1,4-diazabicyclo(2,2,2)octane, as shown above in Step A.
[Bull. Chem. Soc. Japan, 39, 364-366 (1966)]
Step B Synthesis of 2,4-diamino-6-(3,4-dichlorophenylsulfinyl)quinazoline (Compound 81)
A suspension of 5.0 grams (0.011 mole) of the bromine complex of
5 1,4-diazabicyclo(2,2,2)octane in 200 mL of aqueous 70% acetic acid was 'stirred, and 3.4 grams (0.01 mole) of 2,4-diamino-6-(3,4-dichlorophenylthio)quinazoline was added portionwise during about a 1 hour period. Upon completion of addition, the reaction mixture was stirred at ambient temperature for about 20 hours. After this time, the reaction
0 mixture was neutralized with concentrated ammonium hydroxide. The resultant solid was collected by filtration and triturated with methanol. The solid was collected by filtration and dried, yielding 2,4-diamino-6-(3,4dichlorophenylsulfinyl)quinazoline, mp 200°C, dec. The NMR spectrum was consistent with the proposed structure.
AP. Ο Ο 5 Ο 7
EXAMPLE 12
SYNTHESIS OF 2.4-DIAMINO-5-METHYL-6-NITROQUINAZOLINE (COMPOUND 30)
Step A Synthesis of 2-chloro-6-methyl-5-nitrobenzonitrile as an intermediate
Under a nitrogen atmosphere, a stirred solution of aqueous 90% nitric acid was cooled to -35°C, and 40.0 grams (0.264 mole) of 2-chloro-61 0 methylbenzonitrile was added in one portion. The reaction mixture was then allowed to warm to ambient temperature, where it was stirred for about 18 hours. After this time, the reaction mixture was poured into 3000 mL of ice-water. After the ice melted, the resultant solid was collected by filtration and dried. The NMR spectrum of the solid indicated that it was about 75%
5 pure product. The solid was recrystallized twice from methanol, yielding 13.9 grams of 2-chloro-6-methyl-5-nitrobenzonitrile, mp 85.5-87.5°C. The NMR spectrum was consistent with the proposed structure. The filtrates from the recrystallizations were combined and concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using 10% ethyl acetate in petroleum ether. The product-containing fractions were combined and concentrated under reduced pressure, yielding an additional 20.4 grams of 2-chloro-6-methyl-5-nitrobenzonitrile, mp 87.589.5°C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2,4-diamino-6-methyl-5-nitroquinazoline (Compound 30)
AP/P; 9 4/ 0 0 7 9 6
Under a nitrogen atmosphere, a stirred solution 29.5 grams (0.150 3 0 mole) of 2-chloro-6-methyl-5-nitrobenzonitrile and 54.0 grams (0.300 mole) of guanidine carbonate in 1500 mL of 2-ethoxyethanol was heated at reflux during a 3.5 hour period. After this time, the reaction mixture was concentrated under reduced pressure to a residue. The residue was stirred with 300 mL of water, and the resultant solid was collected by
5 filtration. The solid was washed with 50 mL of water and dried under reduced pressure, yielding 27.2 grams of 2,4-diamino-5-methyl-628' nitroquinazoline. The NMR spectrum was consistent with the proposed structure. The reaction was repeated again.
EXAMPLE 13
SYNTHESIS OF 2,4,6-TRIAMINO-5-METHYLQUINAZOLINE (COMPOUND 32)
A mixture of 5.0 grams (0.023 mole) of 2,4-diamino-5-methyl-6nitroquinazoline (prepared in Example 12) and 0.5 gram (catalyst) of 10%
0 palladium on carbon in 200 mL of ethanol was hydrogenated at 45-50°C C using a Parr hydrogenator. The theoretical uptake of hydrogen required about 2.5 hours. The hydrogenation was repeated twice more, using 15.0 grams (0.068 mole) and 11.0 grams (0.050 mole), respectively, of 2,4diamino-5-methyl-6-nitroquinazoline. The total yield of 2,4,6-triamino-51 5 methylquinazoline was 19.5 grams. The NMR spectra were consistent with the proposed structure.
EXAMPLE 14
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-[(3,4,52 0 TRIMETHOXYPHENYLAMINO)METHYL]QUINAZOLINE (COMPOUND 93) ♦
f Step A Synthesis of 2,4-diamino-6-cyano-5-methylquinazoline as an intermediate (7* 25
Under a nitrogen atmosphere, a stirred solution of 2.5 grams (0.013 mole) of 2,4,6-triamino-5-methylquinazoline (prepared in Example 13) and 25 mL of 2N hydrochloric acid (0.050 mole) was cooled to 5°C, and a solution of 1.1 grams (0.016 mole) of sodium nitrite in 4 mL of water was
0 added dropwise. Upon completion of addition, the reaction mixture was stirred at 5°C during a 10 minute period. In a separate reaction vessel, a stirred solution of 14.7 grams (0.225 mole) of potassium cyanide in 70 mL of water was cooled to 5°C, and a solution of 1.4 grams (0.056 mole) of copper(ll) sulfate pentahydrate in 100 mL of water was added dropwise.
5 To this solution was added, portionwise, the reaction mixture containing the quinazoline diazonium salt prepared above. Upon completion of addition,
AP. ο ο 5 ο 7
Γ (
C ρ 25 the reaction mixture was allowed to warm to ambient temperature as it stirred during a 2 hour period. After this time, the reaction mixture was diluted with 60 mL of aqueous 50% potassium carbonate and was extracted with four 700 mL portions of tetrahydrofuran. The combined extracts were acidified with 50 mL of acetic acid, and the mixture was concentrated under reduced pressure to a residual solid. The solid was subjected twice to column chromatography on silica gel. Elution was accomplished in each case with 20% N.N-dimethylformamide in ethyl acetate. The product-containing fractions were combined and concentrated under reduced pressure, yielding 1.1 grams of 2,4-diamino-6-cyano5-methylquinazoline. The NMR spectrum was consistent with the proposed structure; however, it showed that the product was in the form of the acetate salt.
Step B Synthesis of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylaminojmethyljquinazoline (Compound 93)
A mixture of 1.1 grams (0.005 mole) of 2,4-diamino-6-cyano-5methylquinazoline, 4.6 grams (0.025 mole) 3,4,5-trimethoxyaniline and 2.0 grams (catalyst) of Raney nickel (50% slurry in water) in 30 mL of water and 70 mL of acetic acid was hydrogenated at 50 psi of hydrogen for 6 hours using a Parr hydrogenator. After this time the reaction mixture was filtered. The filter cake was slurried with a boiling mixture of 15 mL of water and 35 mL of acetic acid and was then filtered. The filtrates were combined and subjected to thin layer chromatography (TLC). The TLC analysis indicated that a small amount of the starting quinazoline remained unreacted. The filtrate was combined with 1.0 gram of Raney nickel and the mixture was again hydrogenated for an additional 1.5 hours using the Parr hydrogenator. After this time the reaction mixture was filtered and concentrated under reduced pressure to a residual oil. The residual oil was subjected to column chromatography on silica gel. Elution was accomplished initially using 25% N.N-dimethylformamide in ethyl acetate and, finally 40% Ν,Ν-dimethylformamide in ethyl acetate. The productcontaining fractions were combined and concentrated under reduced pressure to a residual solid. The solid was recrystallized from water, yielding 0.5 gram of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenyl96/00/)6 /d/d! V amino)methyl]quinazoline, mp 95-210°C. The NMR analysis was consistent with the proposed structure; however, it indicated that the compound was a complex with acetic acid and water.
NOTE: The compound of Example 14 is known in the literature as Trimetrexate®, for use in treatments of certain kinds of cancers.
[J. Med. Chem., 2£, 1753-1760 (1983)]
EXAMPLE 15
SYNTHESIS OF 2,4-DIAMINO-5-CHLORO-6-[(3,4,5TRIMETHOXYPHENYLMETHYL)IMINO]QUINAZOLINE
COMPOUND 91
Step A Synthesis of 2,4-diamino-5-chloro-6-nitroquinazoline as an intermediate
Nitric acid (90%), 125 mL, was stirred and cooled to -10°C, and 125 mL of 98% sulfuric acid was added dropwise. Upon completion of addition, the reaction mixture temperature was brought to 0°C, and 19.7 grams (0.10 mole) of 2,4-diamino-5-chloroquinazoline (Compound 2, prepared in a manner analogous to that of Step E of Example 1) was added. Upon completion of addition, the reaction mixture was allowed to warm to ambient temperature where it was stirred for about 18 hours. The reaction mixture was then poured into 1500 mL of ice. The resultant mixture was made basic with 700 mL of aqueous 30% ammonia, keeping the temperature below 30°C. The mixture was cooled in an ice-bath, and the resultant solid was collected by filtration. The solid was stirred with 1000 mL of tetrahydrofuran and 500 mL of water. The mixture was filtered to remove a solid. The filtrate was diluted with 500 mL of ethyl acetate and then was concentrated under reduced pressure to a solid residue. The two solids were combined, washed with ethyl acetate, and dried, yielding 22.2 grams of 2,4-diamino-5-chloro-6-nitroquinazoline. The NMR spectrum was consistent with the proposed structure.
Step B1 Synthesis of 2,4,6-triamino-5-chloroquinazoline (Compound 24) as an intermediate
AP. Ο Ο 5 Ο 7
This compound was prepared in a manner analogous to that of Example 13, using 11.0 grams (0.049 mole) of 2,4-diamino-5-chloro-6nitroquinazoline and 1.0 gram of 10% platinum on carbon in 70 mL of
2-methoxyethanol and 130 mL of ethanol, yielding 2,4,6-triamino-5chloroquinazoline.
Step C Synthesis of 2,4-diamino-5-chloro-6-[(3,4,5-trimethoxyphenylmethyl)imino]quinazoline (Compound 91)
C' Under a nitrogen atmosphere, a stirred solution of 3.0 grams (0.014 mole) of 2,4,6-triamino-5-chloroquinazoline and 2.9 grams (0.029 mole) of 3,4,5-trimethoxybenzaldehyde in 30 mL of ethanol was heated at reflux during a 5 hour period. After this time, the resultant slurry was mixed with
50 mL of 2-ethoxyethanol, 70 mL of ethanol, and 2.0 grams (catalyst) of
Raney nickel. The mixture was then hydrogenated at 50 psi of hydrogen during a 5 hour period using a Parr hydrogenator. The mixture was then filtered, and the filter cake was slurried with 50 mL of ethanol. The ethanol was decanted from the catalyst. The remaining solid and catalyst were
0 slurried with an additional 50 mL of ethanol which was then decanted from the catalyst. The decantates were combined with 100 mL of dioxane and 2.0 grams of Raney nickel and hydrogenated during a four hour period, as described above. The reaction mixture was then diluted with 200 mL of dioxane and heated to reflux, at which time complete solution was ~ 25 obtained. The solution was filtered to remove the catalyst. The filtrate was concentrated under reduced pressure to a solid residue. The solid was recrystallized from dioxane and water, yielding 2.4 grams of solid platelets, mp 234-235°C. The NMR spectrum indicated the solid to be 2,4-diamino5-chloro-6-[(3,4,5-trimethoxyphenylmethyl)imino]quinazoline.
EXAMPLE 16
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-(3,5DICHLOROPHENYL)QUINAZOLINE (COMPOUND 116)
Step A Synthesis of 3,5-dichlorophenylboronic acid as an intermediate
AP/PZ 9 4 / 0 0 7 9 6
This compound was prepared in a manner analogous to that of Step C of Example 2, using 20.0 grams (0.073 mole) of 3,5-dichlorophenyl iodide, 32.0 mL of n-butyllithium (0.080 mole - 2.5M in hexanes) and 48.6 mL (0.220 mole) of triisopropyl borate. The yield of 3,5-dichlorophenylboronic acid was 6.7 grams; mp >250 °C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-6-methyl-5-(3,5-dichlorophenyl)1 0 benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step D of Example 2, using 4.3 grams (0.024 mole) of 3,5-dichlorophenylboronic acid, 4.8 grams (0.023 mole) of 2-amino-5-bromo-6-methylbenzonitrile,
5 about 22 mL of aqueous 2M sodium carbonate, and about 0.15 gram (catalyst) of tetrakis(triphenylphosphine)palladium(0) in 50 mL of toluene. The yield of 2-amino-6-methyl-5-(3,5-dichlorophenyl)benzonitrile was 4.4 grams, mp 182 °C. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2,4-diamino-5-methyl-6-(3,5-dichlorophenyl)quinazoline (Compound 116)
This compound was prepared in a manner analogous to that of Step
E of Example 1, using 4.2 grams (0.015 mole) of 2-amino-6-methyl-5-(3,5dichlorophenyl)benzonitrile and 2.0 grams (0.017 mole) of chloroformamidine hydrochloride in about 15 mL of diglyme. The yield of 2,4-diamino-5-methyl-6-(3,5-dichlorophenyl)quinazoline was 2.7 grams, mp >250 °C. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 17
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-[1-CHLORO-2-(4TRIFLUOROMETHYLPHENYL)ETHENYL]QUINAZOLINE (COMPOUND 143)
AP . 0 0 5 0 7
Step A Synthesis of 2-amino-5-iodo-6-methylbenzonitrile as an intermediate
Ο r
c c, 25
This compound was prepared in a manner analogous to that of Step C of Example 1, using 17.5 grams (0.132 mole) of 2-amino-6-methylbenzonitrile (prepared as in Step B of Example 1) and 29.8 grams (0.132 mole) of N-iodosuccinimide in 325 mL of Ν,Ν-dimethylformamide. The yield of 2amino-5-iodo-6-methylbenzonitrile was 28.5 grams. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-5-(trimethylsilylethynyl)-6-methylbenzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step B of Example 6, using 10.0 grams (0.039 mole) of 2-amino-5-iodo-6methylbenzonitrile, 8.3 mL (0.059 mole) of (trimethylsilyl)acetylene, 0.5 gram (catalyst) of bis(triphenylphosphine)palladium(ll) chloride, 0.2 gram (catalyst) of copper(l) iodide, and 21 mL (0.156 mole) of triethylamine in 75 mL of acetonitrile. The yield of 2-amino-5-(trimethylsilylethynyl)-6methylbenzonitrile was 6.6 grams. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2-amino-5-ethynyl-6-methylbenzonitrile as an intermediate
AP/P/ 9 4 / 0 0 7 9 6
A mixture of 1.4 grams (0.006 mole) of 2-amino-5-(trimethylsilylethynyl)-6-methylbenzonitrile and 0.9 gram (0.006 mole) of potassium carbonate in 50 mL of methanol was stirred at ambient temperature for one hour. The reaction mixture was then concentrated under reduced pressure to a residue. The residue was taken up in about 75 mL of water, and the solution was extracted with two 200 mL portions of diethyl ether. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, yielding 1.0 gram of 2amino-5-ethynyl-6-methylbenzonitrile. The NMR spectrum was consistent with the proposed structure. This reaction was repeated several times.
Step D Synthesis of 2-amino-6-methyl-5-[(4-trifluoromethylphenyl)ethynyl]benzonitrile as an intermediate
A solution of 3.5 grams (0.022 mole) of 2-amino-5-ethynyl-65 methylbenzonitrile, 8.4 grams (0.031 mole) of 4-trifluoromethylphenyl iodide, 10.7 grams (0.077 mole) of triethylamine, 0.5 gram (catalyst) of bis(triphenylphosphine)palladium(ll) chloride, and 0.5 gram (catalyst) of copper(l) iodide in 100 mL of acetonitrile was stirred at ambient temperature for about 18 hours. After this time the reaction mixture was
0 concentrated under reduced pressure to a residue. The residue was f' partitioned between ethyl acetate and aqueous 1N hydrochloric acid. The two-layered mixture was filtered to remove a solid. The aqueous layer and (j / the organic layer were separated, and the aqueous layer was washed with ethyl acetate. The ethyl acetate wash was combined with the organic layer,
5 and the combination was washed with an aqueous solution of 10% lithium chloride. The organic layer was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was triturated with methylene chloride and filtered. The filtrate was subjected to column chromatography on silica gel. Elution was
0 accomplished using methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 4.8 grams of 2-amino-6-methyl‘5-[(4-trifluoromethylphenyl)ethynyl]benzonitrile, mp 136-138 °C. The NMR spectrum was consistent with the proposed structure.
c 25
Step E Synthesis of 2,4-diamino-5-methyl-6-[1-chloro-2-(4trifluoromethylphenyl)ethenyl]quinazoline (Compound 143)
This compound was prepared in a manner analogous to that of Step
0 E of Example 1, using 2.7 grams (0.009 mole) of 2-amino-6-methyl-5-[(4trifluoromethylphenyl)ethynyl]benzonitrile and 1.2 grams (0.011 mole) of chloroformamidine hydrochloride in 10 mL of diglyme. Upon completion of the reaction, the reaction mixture was diluted with 200 mL of diethyl ether. The resultant solid was collected by filtration, and was dissolved in a hot
5 mixture of 300 mL of water and 100 mL of n-propanol. The solution was filtered hot through a sintered glass funnel to remove some insoluble
AP.00507 material. The filtrate was then made basic with 100 mL of concentrated ammonium hydroxide. The resultant solid was collected by filtration, and dried at 60 °C under vacuum. The solid was then dissolved in a solution of 10% methanol in methylene chloride, and the solution was subjected to column chromatography on silica gel. Elution was accomplished using 10% methanol in methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 1.6 grams of 2,4-diamino-5-methyl-6-[1-chloro-2-(4-trifluoromethylphenyl)ethenyl]quinazoline, mp >300 °C. The NMR spectrum was
0 consistent with the proposed structure.
EXAMPLE 18
C : SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-(5-CHLOROTHIEN-2YL)QUINAZOLINE (COMPOUND 146)
Step A Synthesis of (5-chlorothien-2-yl)tributyl tin as an intermediate
A stirred solution of 5.1 mL (0.046 mole) of 2-bromo-5-chloro2 0 thiophene in 200 mL of tetrahydrofuran was cooled to -85 °C, and 19.7 mL (0.049 mole) of n-butyllithium (0.049 mole - 2.5M in hexanes) was added dropwise during a 15 minute period. The reaction mixture temperature was ζ maintained at -85 °C to -80 °C throughout the addition. Upon completion of addition, the reaction mixture temperature was maintained at about -80 °C for one hour. After this time, a solution of 12.5 mL (0.046 mole) of tributyltin chloride in 50 mL of tetrahydrofuran was added to the cold reaction mixture during a 10 minute period. Upon completion of addition, the reaction mixture was stirred at -80 °C for one hour, then it was allowed to warm gradually to ambient temperature. The reaction was quenched with an
0 aqueous solution saturated with ammonium chloride, and then the reaction mixture was extracted with three 150 mL portions of diethyl ether. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, yielding 18.4 grams of (5-chlorothien-2-yl)tributyi tin. The NMR spectrum was consistent with the
5 proposed structure.
AP/P/ 9 4/ 0 0 7 9 6
Step B Synthesis of 2-amino-6-methyl-5-(5-chlorothien-2-yl)benzonitrile as an intermediate
A solution of 5.9 grams (0.015 mole) of (5-chlorothien-2-yl)tributyl tin 5 and 3.0 grams (0.015 mole) of 2-amino-5-iodo-6-methylbenzonitrile in 150 mL of toluene was stirred, and 0.2 gram (catalyst) of tetrakis(triphenylphosphine)palladium(O) was added. The reaction vessel was evacuated, and then back-filled with dry nitrogen gas. This process was repeated two more times. The reaction mixture was then heated to reflux where it was
0 stirred for about 18 hours. After this time the reaction mixture was concentrated under reduced pressure to a residue. The residue was dissolved in methylene chloride, and the solution was filtered through a θ fiber-glass pad to remove the catalyst. The filtrate was subjected to column chromatography on silica gel. Elution was accomplished using methylene
5 chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 2.0 grams of 2-amino-6methyl-5-(5-chlorothien-2-yl)benzonitrile, mp 108-110 °C. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2,4-diamino-5-methyl-6-(5-chlorothien-2yl)quinazoline (Compound 146) q This compound was prepared in a manner analogous to that of Step
E of Example 1, using 1.6 grams (0.007 mole) of 2-amino-6-methyl-5-(5& 25 chlorothien-2-yl)benzonitrile and 0.8 gram (0.008 mole) of chloroformamidine hydrochloride in 10 mL of diglyme. The yield of 2,4-diamino-5methyl-6-(5-chlorothien-2-yl)quinazoline was 1.1 grams, mp 270-272 °C, dec. The NMR spectrum was consistent with the proposed structure.
0 EXAMPLE 19
SYNTHESIS OF 2.4-DIAMINO-5-METHYL6-(4-TRIFLUOROMETHYLPHENYLCARBONYL)QUINAZOLINE (COMPOUND 158)
5 Step A Synthesis of 2-amino-5-(4-trifluoromethylphenylcarbonyl)-6methylbenzonitrile as an intermediate
AP.00507 r
© c
25
A mixture of 2.6 grams (0.01 mole) of 2-amino-5-iodo-6-methylbenzonitrile (prepared in Step A of Example 17), 8.3 grams (0.0125 mole) of tetramethylammonium tetra(4-trifluoromethylphenyl)borate, and 0.1 gram (0.0005 mole) of palladium(ll) acetate in 50 mL of Ν,Ν-dimethylformamide is placed in a high pressure reaction vessel. The stirring reaction mixture is then placed under 1 atmosphere of carbon monoxide gas, where it is maintained at about 60 °C for a 30 hour period. After this time, the cooled reaction mixture is removed from the reaction vessel and is filtered to remove catalyst and salts. The filtrate is concentrated under reduced pressure to a residue. The residue is partitioned between methylene chloride and water. The methylene chloride-product solution is then subjected to column chromatography on silica gel. Elution is accomplished with methylene chloride. The product-containing fractions are combined and concentrated under reduced pressure, yielding about 2.0 grams of 2amino-5-(4-trifluoromethylphenylcarbonyl)-6-methylbenzonitrile.
Step B Synthesis of 2,4-diamino-5-methyl-6-(4-trifluorophenylcarbonyl)quinazoline (Compound 158)
This compound is prepared in a manner analogous to that of Step E of Example 1, using 2.0 grams (0.009 mole) of 2-amino-5-(4-trifluoromethylphenylcarbonyl)-6-methylbenzonitrile and 0.9 gram (0.009 mole) chloroformamidine hydrochloride in 20 mL of diglyme, yielding 2,4diamino-5-methyl-6-(4-trifluorophenylcarbonyl)quinazoline.
EXAMPLE 20
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-(3-FLUORO-5TRIFLUOROMETHYLPHENYL)QUINAZOLINE (COMPOUND 188)
Step A Synthesis of 3-fluoro-5-trifluoromethylphenylboronic acid as an intermediate
A crystal of iodine and 0.5 gram (0.021 mole) of magnesium turnings were placed in a reaction vessel containing 10 mL of tetrahydrofuran. To
ΑΡ/Γ/ 9 4 / 0 0 7 9 6 1 0 ι
c c
O 25 this was added dropwise 2 mL of a solution of 5.0 grams (0.021 mole) of 3fluoro-5-trifluoromethylphenyl bromide in 65 mL of tetrahydrofuran. The Grignard formation was initiated by warming the reaction vessel to about 45 °C. The remaining 3-fluoro-5-trifluoromethylphenyl bromide tetrahydrofuran solution was added portionwise at a rate which maintained gentle reflux of the reaction mixture.
In a second reaction vessel, 40 mL of tetrahydrofuran was cooled to -78 °C, and 2.3 mL (0.021 mole) of trimethyl borate was added dropwise as the Grignard reagent of 3-fluoro-5-trifluoromethylphenyl bromide prepared above was transferred into the second reaction vessel using a cannula. The temperature of the reaction mixture was maintained below -60 °C during the additions. Upon completion of the additions, the reaction mixture was again cooled to -78 °C, where it was stirred for about 45 minutes. After this time, the reaction mixture was allowed to warm to ambient temperature. The reaction mixture was then poured into about 200 mL of water and was made acidic with aqueous 5% hydro-chloric acid. The mixture was extracted with four 100 mL portions of ethyl acetate. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, yielding 3.3 grams of 3fluoro-5-trifluoromethylphenylboronic acid, mp 167-168 °C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-amino-6-methyl-5-(3-fluoro-5trifluoromethylphenyl)benzonitrile as an intermediate
Under a dry nitrogen atmosphere, 0.5 gram (0.0004 mole) of tetrakis(triphenyl-phosphine)palladium(0) was added to a stirred mixture of 2.8 grams (0.0132 mole) of 2-amino-5-bromo-6-methylbenzonitrile (prepared as in Step C of Example 1), 35 mL ol aqueous 2M sodium carbonate and 50 mL of toluene. To this was then added dropwise a solution of 3.3 grams (0.0159 mole) of 3-fluoro-5-trifluoromethylphenylboronic acid in 10 mL of ethanol. Upon completion of addition, the reaction mixture was warmed to about 80 °C, where it was stirred for seven hours. After this time the reaction mixture was poured into 200 mL of water. The mixture was then extracted with four 100 mL portions of ethyl acetate. The combined extracts were dried with magnesium sulfate and filtered. The
AP.00507 filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished with methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 4.0 grams of 2-amino-6-methyl-5-(3-fluoro-5-trifluoromethylphenyl)-.
benzonitrile, mp 96-97 °C. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2,4-diamino-5-methyl-6-(3-fluoro-510 trifluoromethylphenylj-quinazoline (Compound 188)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 3.7 grams (0.013 mole) of 2-amino-6-methyl-5-(3fluoro-5-trifluoromethylphenylbenzonitrile and 1.7 grams (0.015 mole) of
5 chloroform-amidine hydrochloride in 25 mL of diglyme. The yield of 2,4diamino-5-methyl-6-(3-fluoro-5-trifluoromethylphenyl)quinazoline was 2.8 grams, mp 225-226 °C. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 21
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-[3-(4FLUOROPHENYL)PHENYLJQUINAZOLINE (COMPOUND 196)
5 Step A Synthesis of 3-(4-fluorophenyl)phenyl bromide as an intermediate
AP/P/ 94/00796
This compound was prepared in a manner analogous to that of Step D of Example 2, using 6.2 grams (0.044 mole) of 4-fluorophenylboronic
0 acid (commercially available), 25.0 grams (0.100 mole) of 1,3dibromobenzene, 0.2 gram (catalyst) of tetrakis(triphenylphosphine)palladium(O), 75 mL of aqueous 2M sodium carbonate, and 75 mL of toluene. The yield of 3-(4-fluorophenyl)phenyl bromide was 7.1 grams. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 3-(4-fluorophenyl)phenylboronic acid as an intermediate r
c
5 c· o 25
This compound was prepared in a manner analogous to that of Step C of Example 2, using 7.1 grams (0.028 mole) of 3-(4-fluorophenyl)phenyl bromide, 17 mL (0.034 mole) of n-butyllithium (2.0 M in hexanes), and 9.5 mL (0.084 mole) of trimethyl borate in 100 mL of tetrahydrofuran. The yield of 3-(4-fluorophenyl)phenylboronic acid was about 3.5 grams. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2-amino-6-methyl-5-[3-(4fluorophenyl)phenyl]benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step D of Example 2, using 3.4 grams (0.016 mole) of 3-(4fluorophenyl)phenylboronic acid, 3.3 grams (0.016 mole) of 2-amino-5bromo-6-methylbenzonitrile, 0.2 gram (catalyst) of tetrakis(triphenylphosphine)palladium(O), 50 mL of aqueous 2M sodium carbonate, and 50 mL of toluene. The yield of 2-amino-6-methyl-5-[3-(4fluorophenyl)phenyl]benzonitrile was 4.8 grams. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of 2,4-diamino-5-methyl-6-[3-(4fluorophenyl)phenyl]quinazoline (Compound 196)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 2.0 grams (0.007 mole) of 2-amino-6-methyl-5-[3-(4fluorophenyl)phenyl]benzo-nitrile and 0.8 gram (0.007 mole) of chloroformamidine hydrochloride in 10 mL of diglyme. The yield of 2,4diamino-5-methyl-6-[3-(4-fluorophenyl)phenyl]quinazoline was 0.5 gram. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 22
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-[3-(4CHLOROPHENOXY)PHENYL]QUINAZOLINE (COMPOUND 205)
AP. Ο Ο 5 Ο 7
Step A Synthesis of 3-(4-chlorophenoxy)phenyl bromide as an intermediate
Under a nitrogen atmosphere, a solution of 13.6 grams (0.106 mole) 5 of 4-chlorophenol in 50 mL of diglyme was stirred, and 24.1 mL (0.106 mole) of methanolic 25% sodium methoxide was added dropwise. Upon completion of addition, the reaction mixture was heated to about 165 °C to remove methanol. After the methanol was removed, the heating was ceased, and 25.0 grams (0.106 mole) of 1,3-dibromobenzene and 1.3
0 grams of cuprous bromide were added. Upon completion of the additions, ' the reaction mixture was heated to reflux where it was stirred for about 21 hours. The reaction mixture was then cooled and filtered. The filter cake C was washed with diethyl ether, and the wash was combined with the filtrate. The combination was extracted with two 20 mL portions of aqueous 1 5 20% sodium hydroxide and then with two 75 mL portions of an aqueous solution saturated with sodium chloride. The organic layer was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residual oil. The oil was distilled under vacuum, yielding about 9.0 grams of 3-(4-chlorophenoxy)phenyl bromide, bp 110 °C / 0.5 mm Hg. The NMR spectrum was consistent with the proposed structure.
Q Step B Synthesis of 3-(4-chlorophenoxy)phenylboronic acid as an intermediate 25
This compound was prepared in a manner analogous to that of Step C of Example 2, using 9.0 grams (0.032 mole) of 3-(4-chlorophenoxy)phenyl bromide, 14 mL (0.035 mole) of n-butyllithium (2.5M in hexanes), and 10.4 mL (0.095 mole) of trimethyl borate in 100 mL of tetrahydrofuran.
0 The yield of 3-(4-chlorophenoxy)phenylboronic acid was about 7.6 grams. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of 2-amino-6-methyl-5-[3-(4-chlorophenoxy)phenyljbenzonitrile as an intermediate
AP/P/ 94/00796
This compound was prepared in a manner analogous to that of Step D of Example 2, using 7.6 grams (0.031 mole) of 3-(4chlorophenoxy)phenylboronic acid, 6.5 grams (0.031 mole) of 2-amino-5bromo-6-methylbenzonitrile, about 0.2 gram (catalyst) of tetrakis(triphenylphosphine)palladium(0), about 30 mL of aqueous 2M sodium carbonate, and about 50 mL of toluene. The yield of 2-amino-6methyl-5-[3-(4-chlorophenoxy)-phenyl]benzonitrile was 2.0 grams. The NMR spectrum was consistent with the proposed structure.
0 Step E Synthesis of 2,4-diamino-5-methyl-6-[3-(4chlorophenoxy)phenyl]quinaz-oline (Compound 205)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 1.8 grams (0.005 mole) of 2-amino-6-methyl-5-[3-(41 5 chloro-phenoxy)phenyl]benzonitrile and 0.6 gram (0.005 mole) of chloroformamidine hydrochloride in about 10 mL of diglyme. The yield of
2,4-diamino-5-methyl-6-[3-(4-chlorophenoxy)phenyl]quinazoline was 0.9 gram. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 23
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-(6-CHLORO-2,3-DIHYDRO2,2-DIMETHYLBENZOFURAN-4-YL)QUINAZOLINE (COMPOUND 210)
Step A Synthesis of 2-methyl-3-(3-chloro-2-cyanophenoxy)-1propene as an intermediate
A solution of 30.0 grams (0.174 mole) of 2,6-dichlorobenzonitrile and 14.7 mL (0.174 mole) of 2-methyl-2-propen-1-ol in 200 mL of dimethyl
0 sulfoxide was stirred, and 12.7 grams (0.191 mole) of 85% potassium hydroxide was added portionwise during a 5 minute period. During the addition, the reaction mixture temperature rose from 20 °C to about 35 °C. Upon completion of the addition, the reaction mixture was stirred at ambient temperature for about 18 hours. After this time the reaction mixture
5 was poured into 600 mL of water. The mixture was filtered to collect a solid. The solid was washed with water and dried under vacuum, yielding
AP.00507
33.9 grams of 2-methyl-3-(3-chloro-2-cyanophenoxy)-1-propene. The
NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 6-chloro-7-cyano-2,3-dihydro-2,25 dimethylbenzofuran as an intermediate
A stirred mixture of 33.9 grams (0.163 mole) of 2-methyl-3-(3-chloro2-cyano-phenoxy)-1-propene and 0.2 gram (0.0017 mole) of magnesium chloride was warmed to 180 °C during a one hour period, where it was
0 stirred for about six hours. The product, which sublimed to the top of the reaction vessel, was subjected to column chromatog-raphy on silica gel. Elution was accomplished using 1:1 methylene chloride and petroleum ether. The product-containing fractions were combined and concentrated under reduced pressure, yielding 25.8 grams of 6-chloro-7-cyano-2,31 5 dihydro-2,2-dimethylbenzofuran. The NMR spectrum was consistent with the proposed structure.
Step C. Synthesis of 7-aminocarbonyl-6-chloro-2,3-dihydro-2,2dimethylbenzofuran as an intermediate
A strirred solution of 10.0 grams (0.048 mole) of 6-chloro-7-cyano2,3-dihydro-2,2-dimethylbenzofuran 4h 200 mL of 2-methyl-2-propanol was warmed to reflux, and 9.5 grams (0.17 mole) of 85% potassium hydroxide was added in one portion. Upon completion of addition, the reaction
5 mixture was heated at reflux for about 75 minutes. The reaction mixture was then cooled and poured into 400 mL of water that was cooled in an ice bath. The resultant solid was collected by filtration and dried under vacuum, yielding 8.2 grams of 7-aminocarbonyl-6-chloro-2,3-dihydro-2,2dimethylbenzofuran. The NMR spectrum was consistent with the proposed
0 structure.
Step D Synthesis of 7-amino-6-chloro-2,3-dihydro-2,2dimethylbenzofuran as an intermediate
A stirred solution of 5.8 grams (0.145 mole) of sodium hydroxide in 100 mL of water was cooled to 0 °C, and 7.3 grams (0.045 mole) of
AP/P/ 94/00796 bromine was added dropwise during a 5 minute period. Upon completion of addition, the mixture was stirred for 5 minutes, and an emulsion of 8.2 grams (0.036 mole) of 7-aminocarbonyl-6-chloro-2,3-dihydro-2,2dimethylbenzofuran in 75 mL of dioxane was added portionwise during a 15 minute period. Upon completion of addition, the reaction mixture was stirred at 0 °C for one hour. The reaction mixture was warmed to 75 °C during a two hour period, where it was stirred for 19 hours. After this time the reaction mixture was cooled and poured into 300 mL of water. The mixture was then extracted with two 200 mL portions of ethyl acetate. The combined extracts were washed with an aqueous solution saturated with sodium chloride and dried with magnesium sulfate. The mixture was filtered and concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using methylene chloride. The product containing fractions were combined and concentrated under reduced pressure, yielding 4.5 grams of 7-amino-6-chloro-2,3-dihydro-2,2dimethylbenzofuran. The NMR spectrum was consistent with the proposed structure.
Step E Synthesis of 7-amino-4-bromo-6-chloro-2,3-dihydro-2,2dimethylbenzofuran as an. intermediate
This compound was prepared in a manner analogous to that of Step C of Example 1, using 4.5 grams (0.023 mole) of 7-amino-6-chloro-2,3dihydro-2,2-dimethylbenzofuran and 4.1 grams (0.023 mole) of Nbromosuccinimide in 50 mL of Ν,Ν-dimethylformamide. The yield of 7amino-4-bromo-6-chloro-2,3-dihydro-2,2-dimethylbenzofuran was 5.1 grams. The NMR spectrum was consistent with the proposed structure.
Step F Synthesis of 4-bromo-6-chloro-2,3-dihydro-2,2dimethylbenzofuran as an intermediate
A stirred solution of 5.1 grams (0.018 mole) of 7-amino-4-bromo-6chloro-2,3-dihydro-2,2-dimethylbenzofuran and 25 mL of toluene in 100 mL of ethanol was cooled in an ice bath, and 2 mL (0.036 mole) of concentrated sulfuric acid was added slowly. Upon completion of addition,
AP. Ο Ο 5 Ο 7
2.0 grams (0.029 mole) of sodium nitrite was then added. The ice bath was then removed, and the reaction mixture was warmed to 75 °C, where it stirred for 30 minutes. After this time the reaction mixture was warmed to 95 °C, where it stirred for one hour. The reaction mixture was then cooled and poured into 200 mL of water. The mixture was extracted with two 150 mL portions of diethyl ether. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using petroleum
0 ether. The product-containing fractions were combined and concentrated f' under reduced pressure, yielding 3.6 grams of 4-bromo-6-chloro-2,3dihydro-2,2-dimethylbenzofuran. The NMR spectrum was consistent with C the proposed structure.
5 Step G Synthesis of 6-chloro-2,3-dihydro-2,2-dimethylbenzofuran-4ylboronic acid as an intermediate
This compound was prepared in a manner analogous to that of Step C of Example 2, using 3.6 grams (0.014 mole) of 4-bromo-6-chloro-2,320 dihydro-2,2-dimethylbenzofuran, 5.5 mL (0.014 mole) of n-butyllithium (2.5M in hexanes), and 4.7 mL (0.042 mole) of trimethyl borate in 75 mL of tetrahydrofuran. The yield of 6-chloro-2,3-dihydro-2,2-dimethylbenzofuranq 4-ylboronic acid was 3.0 grams. The NMR spectrum was consistent with the proposed structure.
© 25
Step H Synthesis of 2-amino-6-methyl-5-(6-chloro-2,3-dihydro-2,2dimethylbenzofuran-4-yl)benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step
0 D of Example 2, using 3.0 grams (0.013 mole) of 6-chloro-2,3-dihydro-2,2dimethyl-benzofuran-4-yl-boronic acid, 2.1 grams (0.031 mole) of 2-amino5-iodo-6-methylbenzonitrile (prepared as in Step A of Example 17), 0.12 gram (catalyst) of tetrakis(triphenylphosphine)pallad-ium(0), 10 mL of aqueous 2M sodium carbonate, and 100 mL of toluene. The yield of 23 5 amino-6-methyl-5-(6-chloro-2,3-dihydro-2,2-dimethylbenzofuran-4AP/P/ 9 4 / 0 0 7 9 6 rc c
o 25 yl)benzonitrile was 1.9 grams. The NMR spectrum was consistent with the proposed structure.
Step I Synthesis of 2,4-diamino-5-methyl-6-(6-chloro-2,3-dihydro2,2-dimethylbenzofuran-4-yl)quinazoline (Compound 210)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 1.7 grams (0.005 mole) of 2-amino-6-methyl-5-(6chloro-2,3-dihydro-2,2-dimethylbenzofuran-4-yl)benzonitrile and 0.8 gram (0.006 mole) of chloroformamidine hydrochloride in 15 mL of diglyme. The yield of 2,4-diamino-5-methyl-6-(6-chloro-2,3-dihydro-2,2dimethylbenzofuran-4-yl)quinazoline was 1.2 grams. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 24
SYNTHESIS OF 2,4-DIAMINO-7-FLUORO-5-METHYL-6-[3,5DI(TRIFLUOROMETHYL)PHENYL]QUINAZOLINE (COMPOUND 214)
Step A Synthesis of 5-fluoro-2-methylcarbonylamino-3methylnitrobenzene as an intermediate
Stirred acetic anhydride, 300 mL, was cooled to about 7 °C, and 25.1 grams (0.20 mole) of 4-fluoro-2-methylaniline was added dropwise during a 30 minute period. Upon completion of addition, the reaction mixture was stirred at about 10 °C for an additional 15 minutes. In a separate reaction vessel, acetyl nitrate was prepared by the dropwise addition of 14.9 mL of 90% nitric acid to 30 mL of stirred, cold (0 -15 °C) acetic anhydride during a 15 minute period. The so-prepared acetyl nitrate was cooled to about -5 °C, placed in a dropping funnel, and added dropwise during a 30 minute period to the 2-methylaniline solution. Upon completion of addition, the reaction mixture was stirred an additional 5 hours. After this time the reaction mixture was poured into 400 grams of ice. The resultant solid was collected by filtration, washed with water, and dried at 60 °C under vacuum, yielding 23.0 grams of 5-fluoro-2AP .0 0 5 0 7
Ο
C ·
Ο
Ο 25 methylcarbonylamino-3-methylnitrobenzene, mp 167-172 °C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 4-fluoro-2-nitro-6-methylaniline as an intermediate
A stirred solution of 22.4 grams (0.106 mole) of 5-fluoro-2methylcarbonyl-amino-3-methylnitrobenzene, 100 mL of concentrated hydrochloric acid, and 100 mL of ethanol was heated at reflux for about 17 hours. The reaction mixture was cooled and poured into 500 grams of ice. The mixture was made basic with aqueous 50% sodium hydroxide. The resultant solid was collected by filtration and was thoroughly washed with water. The solid was dried at about 60 °C under vacuum, yielding 17.0 grams of 4-fluoro-2-nitro-6-methylaniline, mp 111-113 °C. The NMR spectrum was consistent with the proposed structure. The reaction was repeated to obtain more product.
Step C Synthesis of 4-fluoro-2-nitro-6-methylphenyl iodide as an intermediate
A mixture of 4.4 grams (0.026 mole) of 4-fluoro-2-nitro-6methylaniline, 13.2 grams (0.052 mole) of iodine, and 5.5 grams (0.029 mole) of copper(l) iodide in 125 mL of acetonitrile was stirred, and a solution of 4.6 mL (0.039 mole) of tert- butyl nitrite in 25 mL of acetonitrile was added dropwise during a 10 minute period. Upon completion of addition, the reaction mixture was stirred at ambient temperature for about 16 hours. After this time the reaction mixture was poured into 300 mL of water. Excess iodine was destroyed using sodium meta-bisulfite. The mixture was then extracted with two 250 mL portions of diethyl ether. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using 1:3 methylene chloride : petroleum ether. The product-containing fractions were combined and concentrated under reduced pressure, yielding 3.4 grams of 4-fluoro-2-nitro-6-methylphenyl
AP/P/ 9 4/ 0 0 7 9 6 iodide. The NMR spectrum was consistent with the proposed structure. The reaction was repeated to obtain more product.
Step D Synthesis of 4-fluoro-2-nitro-6-methylbenzonitrile as an 5 intermediate
A stirred mixture of 19.0 grams (0.068 mole) of 4-fluoro-2-nitro-6methylphenyl iodide and 7.0 grams (0.078 mole) of copper(l) cyanide in 100 mL of Ν,Ν-dimethylformamide was heated at 150-155 °C for 30
0 minutes. The reaction mixture was then diluted with 400 mL of water and 100 mL of ethyl acetate. The mixture was filtered, and the filtrate was placed in a separatory funnel. The organic layer was separated, and the
C aqueous layer was washed with 200 mL of ethyl acetate. The combined wash and organic layer was then washed with three 150 mL portions of
5 aqueous 5% lithium chloride. The mixture was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residue. The residue was subjected to column chromatography on silica gel. Elution was accomplished using 1:1 methylene chloride : petroleum ether. The product-containing fractions were combined and
0 concentrated under reduced pressure, yielding 12.8 grams of 4-fluoro-2nitro-6-methylbenzonitrile, mp 61-63 °C. The NMR spectrum was consistent with the proposed structure.’
Step E Synthesis of 2-amino-4-fluoro-6-methylbenzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step B of Example 1, using 12.5 grams (0.069 mole) of 4-fluoro-2-nitro-6methylbenzonitrile, 25.4 mL (0.251 mole) of cyclohexene, 1.9 grams
0 (catalyst) of 10% palladium on charcoal, and 10 mL of water in 200 mL of ethanol. The yield of 2-amino-4-fluoro-6-methylbenzonitrile was 2.0 grams. The NMR spectrum was consistent with the proposed structure.
Step F Synthesis of 2-amino-5-bromo-4-fluoro-6-methylbenzonitrile 3 5 as an intermediate
AP. Ο Ο 5 Ο 7
ΛΓ
C'· 25
This compound was prepared in a manner analogous to that of Step C of Example 1, using 0.5 gram (0.003 mole) of 2-amino-4-fluoro-6methylbenzonitrile and 0.6 gram (0.004 mole) of N-bromosuccinimide in 30 mL of N.N-dimethylformamide. The yield of 2-amino-5-bromo-4-fluoro-6methylbenzonitrile was 0.7 gram. The NMR spectrum was consistent with the proposed structure.
Step G Synthesis of 2-amino-4-fluoro-6-methyl-5-[3,5di(trifluoromethyl)phenyl]benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step D of Example 2, using 1.3 grams (0.005 mole) of 3,5di(trifluoromethyl)phenylboronic acid, (commerc-ially available) 0.7 gram (0.003 mole) of 2-amino-5-bromo-4-fluoro-6-methylbenzonitrile , 0.2 gram (catalyst) of tetrakis(triphenylphosphine)palladium(0), 4.7 mL (0.009 mole) of aqueous 2M sodium carbonate, and 50 mL of toluene. The yield of 2amino-4-fluoro-6-methyl-5-[3,5-di(trifluoromethyl)phenyl]benzonitrile was 0.9 gram. The NMR spectrum was consistent with the proposed structure.
Step H Synthesis of 2,4-diamino-7-fluoro-5-methyl-6-[3,5di(trifluoromethyl)phenyl]-quinazoline (Compound 214)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 0.9 gram (0.002 mole) of 2-amino-4-fluoro-6-methyl5-[3,5-di(trifluoromethyl)phenyl]benzonitrile and 0.3 gram (0.003 mole) of chloroformamidine hydrochloride in 6 mL of diglyme. The yield of 2,4diamino-7-fluoro-5-methyl-6-[3,5-di(trifluoromethyl)-phenyl]quinazoline was 0.4 grams, mp 224-225 °C. The NMR spectrum was consistent with the proposed structure.
AP/P/ 9 4/ 0 0 7 9 6
EXAMPLE 25
SYNTHESIS OF 2,4-DI[(1,1-DIMETHYLETHOXY)CARBONYLAMINO]-5METHYL-6-[3,5-DI(TRIFLUOROMETHYL)PHENYL]QUINAZOLINE (COMPOUND 217)
Γ ©
5 r‘ ο 25
A stirred mixture of 2.00 grams (0.0050 mole) of 2,4-diamino-5methyl-6-[3,5-di(trifluoromethyl)phenyl]quinazoline (Compound 63), 0.06 gram (0.0005 mole) of dimethylaminopyridine, and 10.00 grams (0.0458 mole) of di-tert-butyl dicarbonate was heated at 75 °C for about 6 hours. The reaction mixture was cooled and dissolved in ethyl acetate. The solution was passed through a column of silica gel. Elution was accomplished using ethyl acetate. The eluate was concentrated under reduced pressure to a residue. The residue was triturated with hexane to remove unreacted di-tert-butyl dicarbonate. The yield of 2,4-di[(1,1 dimethylethoxy)carbonylamino]-5-methyl-6-[3,5di(trifluoromethyl)phenyl]quinazoline was 1.2 grams. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 26
SYNTHESIS OF 2,4-DIAMINO-5-(1-METHYLETHYL)-6-[3,5DI(TRIFLUOROMETHYL)PHENYL]QUINAZOLINE (COMPOUND 219)
Step A Synthesis of 2-methylcarbonylamino-3-(1-methylethyl)nitrobenzene as an intermediate
This compound was prepared in a manner analogous to that of Step A of Example 24, using 19.1 grams (0.141 mole) of 2-(1-methylethyl)aniline and 7.9 mL (0.169 mole) of 90% nitric acid in about 85 mL of acetic anhydride. The yield of 2-methylcarbonylamino-3-(1methylethyl)nitrobenzene was 30.0 grams. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 2-nitro-6-(1 -methylethyQaniline as an intermediate
This compound was prepared in a manner analogous to that of Step B of Example 24, using 30.0 grams (0.135 mole) of 2-methylcarbonylamino-3-(1-methylethyl)nitrobenzene, 50 mL of concentrated hydrochloric acid, and 50 mL of ethanol. The yield of 2-nitro-6-(1-methylethyl)aniline
AP.00507 was 12.8 grams. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 2-nitro-6-(1-methylethyl)phenyl iodide as an 5 intermediate
This compound was prepared in a manner analogous to that of Step C of Example 24, using 10.7 grams (0.059 mole) 2-nitro-6-(1methylethyl)aniline, 10.5 mL (0.089 mole) of tert.-butyl nitrite, and 15.0
0 grams (0.059 mole) of iodine in 250 mL of acetonitrile. The yield of 2-nitro6-(1-methylethyl)phenyl iodide was 15.2 grams. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of 2-nitro-6-(1-methylethyl)benzonitrile as an 15 intermediate
This compound was prepared in a manner analogous to that of Step D of Example 24, using 15.0 grams (0.052 mole) of 2-nitro-6-(1methylethyl)phenyl iodide and 5.4 mL (0.060 mole) of copper(l) cyanide in
75 mL of N,N-dimethylformamide. The yield of 2-nitro-6-(1methylethyl)benzonitrile was 9.3 grams. The NMR spectrum was consistent with the proposed structure.
Step E Synthesis of 2-amino-6-(1-methylethyl)benzonitrile as an
5 intermediate
This compound was prepared in a manner analogous to that of Step B of Example 1, using 9.3 grams (0.049 mole) of 2-nitro-6-(1methylethyl)benzonitrile 18.0 mL (0.178 mole) of cyclohexene, 2.0 grams
0 (catalyst) of 10% palladium on charcoal, and 10 mL of water in 250 mL of ethanol. The yield of 2-amino-6-(1-methylethyl)benzonitrile was 7.4 grams. The NMR spectrum was consistent with the proposed structure.
Step F
AP/P/ 94/00796
Synthesis of 2-amino-5-bromo-6-(1-methylethyl)benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step C of Example 1, using 7.0 grams (0.044 mole) of 2-amino-6-(1methylethyl)benzonitrile and 7.8 grams (0.044 mole) of Nbromosuccinimide in 150 mL of Ν,Ν-dimethylformamide. The yield of 25 amino-5-bromo-6-(1-methylethyl)benzonitrile was 8.4 grams, rap 82-85 °C. The NMR spectrum was consistent with the proposed structure.
Step G Synthesis of 2-amino-6-(1-methylethyl)-5-[3,5di(trifluoromethyl)phenyl]benzonitrile as an intermediate
This compound was prepared in a manner analogous to that of Step D of Example 2, using 3.1 grams (0.011 mole) of 3,5-di(trifluoromethyl)phenylboronic acid, 1.8 grams (0.008 mole) of 2-amino-5-bromo-6-(1methylethyl)benzonitrile, 0.3 gram (catalyst) of tetrakis(triphenyl1 5 phosphine)palladium(O), 12.0 mL (0.024 mole) of aqueous 2M sodium carbonate, and 200 mL of toluene. The yield of 2-amino-6-(1-methylethyl)5-[3,5-di-(trifluoromethyl)phenyl]benzonitrile was 2.2 grams. The NMR spectrum was consistent with the proposed structure.
Step H Synthesis of 2,4-diamino-5-(1-methylethyl)-6-[3,5di(trifluoromethyl)phenyl]quinazoline (Compound 219)
This compound was prepared in a manner analogous to that of Step E of Example 1, using 1.9 grams (0.005 mole) of 2-amino-6-(125 methylethyl)-5-[3,5-di(trifluoromethyl)phenyl]benzonitrile and 0.7 gram (0.006 mole) of chloroformamidine hydrochloride in 25 mL of diglyme. The yield of 2,4-diamino-5-(1 -methylethyl)-6-[3,5-di(trifluoromethyl)phenyljquinazoline was 0.4 grams, mp 212-214 °C. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 27
SYNTHESIS OF 2,4-DIAMINO-5-METHYL-6-(2,3-DIHYDRO-2,2DIMETHYL-3-BENZOFURANON-4-YL)QUINAZOLINE (COMPOUND 212)
AP. Ο 0 5 Ο 7
Step A Synthesis of 7-amino-4-bromo-2,3-dihydro-2,2dimethylbenzofuran as an intermediate
A stirred solution of 10.0 grams (0.061 mole) of 7-amino-2,3-dihydro5 2,2-dimethylbenzofuran in 150 mL of Ν,Ν-dimethylformamide was cooled in an ice-water bath, and a solution of 10.9 grams (0.061 mole) of Nbromosuccinimide in 50 mL of Ν,Ν-dimethylformamide was added in one portion. Upon completion of addition, the reaction mixture was maintained in the ice-water bath for about one hour After this time the reaction mixture
0 was poured into about 600 mL of water. The mixture was then extracted f with two 200 mL portions of diethyl ether. The combined extracts were washed with two 100 mL portions of an aqueous 10% lithium chloride θ solution. The organic layer was dried with magnesium sulfate and filtered.
The filtrate was concentrated under reduced pressure, yielding 12.3 grams 15 of 7-amino-4-bromo-2,3-dihydro-2,2-dimethylbenzofuran. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 4-bromo-2,3-dihydro-2,2-dimethylbenzofuran as an intermediate
A stirred solution of 12.3 grams (0.051 mole) of 7-amino-4-bromo2,3-dihydro-2,2-dimethylbenzofuran and 30 mL of toluene in 200 mL of ethanol was cooled in an ice-bath and 5.6 mL (0.102 mole) of concentrated
C sulfuric acid was added slowly, followed by 5.6 grams (0.082 mole) of
5 sodium nitrite. Upon completion of addition, the ice-bath was removed, and the reaction mixture was warmed to 50 °C. The reaction mixture temperature was then brought to about 75 °C, where it was stirred for 30 minutes. After this time the reaction mixture was heated at reflux for one hour and then was poured into 200 mL of water. The mixture was extracted
0 with two 150 mL portions of diethyl ether. The combined extracts were dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a residual oil. The oil was subjected to column chromatography on silica gel. Elution was accomplished using petroleum ether. The product-containing fractions were combined and concentrated
5 under reduced pressure, yielding 3.6 grams of 4-bromo-2,3-dihydro-2,2AP/P/ 9 4/ 0 0 7 9 6 dimethylbenzofuran. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 4-bromo-2,3-dihydro-2,2-dimethyl-35 benzofuranone as an intermediate
Under a nitrogen atmosphere, a stirred solution of 3.0 grams (0.013 mole) 4-bromo-2,3-dihydro-2,2-dimethylbenzofuran, 10.7 grams (0.039 mole).of potassium persulfate, and 3.3 grams (0.013 mole) of copper(ll)
0 sulfate pentahydrate in 30 mL of water and 30 mL of acetonitrile was heated at reflux for one hour. After this time the reaction mixture was poured into 200 mL of water. The mixture was then extracted with one 200 mL portion of diethyl ether. The extract was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to a
5 residual oil. The oil was subjected to column chromatography on silica gel.
Elution was accomplished using 1:1 petroleum ether and methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 2.1 grams of 4-bromo-2,3dihydro-2,2-dimethyl-3-benzofuranone. The NMR spectrum was consistent
0 with the proposed structure. Steps A through C were repeated.
Step D Synthesis of 2,4-diamino-5-methylquinazoline (compound 27) as an intermediate
5 This compound was prepared in a manner analogous to that of Step
E of Example 1, using 10.0 grams (0.076 mole) of 2-amino-6methylbenzonitrile (prepared as in Example 1, Step B), and 10.0 grams (0.087 mole) of chloroformamidine hydrochloride in 40 mL of diglyme, yielding 11.5 grams of 2,4-diamino-5-methylquinazoline. The NMR
0 spectrum was consistent with the proposed structure.
Step E Synthesis of 2,4-diamino-6-acetoxymercurio-5methylquinazoline as an intermediate
5 A solution of 10.0 grams (0.057 mole) of 2,4-diamino-5methylquinazoline and 18.2 grams (0.057 mole) of mercuric acetate in 125
AP. Ο Ο 5 Ο 7 mL of acetic acid is stirred at ambient temperature for about 18 hours. After this time the reaction mixture is poured into 1000 mL of water. The resultant precipitate is collected by filtration and dried, yielding 2,4diamino-6-acetoxymercurio-5-methylquinazoline.
Step F Synthesis of (2,4-diamino-5-methylquinazolin-6-yl)boronic acid as an intermediate
A solution of 17.3 grams (0.040 mole) of 2,4-diamino-61 0 acetoxymercurio-5-methylquinazoline and 38.3 mL (0.400 mole) of boranetetrahydrofuran complex (1.0M in tetrahydrofuran) in 1000 mL of tetrahydrofuran is stirred at ambient temperature for about 30 minutes. The reaction mixture is then poured into water. The resultant precipitate is collected by filtration and dried, yielding (2,4-diamino-5-methylquinazolin1 5 6-yl)boronic acid.
NOTE: The method of S.W. Breuer and F.G. Thorpe (Tetrahedron Lett.No. 42, pp 3719-3720, 1974) is used to prepare 2,4-diamino-52 0 methylquinazolin-6-yl)boronic acid from its 6-acetoxymercurio derivative.
Step G Synthesis of 2,4-diamino-5-methyl-6-(2,3-dihydro-2,2dimethyi-3-benzofuranon-4-yl)quinazoline (compound 212)
5 A solution of 2.1 grams (0.010 mole) of (2,4-diamino-5methylquinazolin-6-yl)boronic acid in 25 mL of Ν,Ν-dimethylformamide is stirred, and 2.1 grams (0.009 mole) of 4-bromo-2,3-dihydro-2,2-dimethyl-3benzofuranone (prepared in Step C of this Example), 2.8 grams (0.020 mole) of potassium carbonate, and 0.31 gram (catalyst-3 mole %) of
0 tetrakis(triphenylphosphine)palladium(0) are added. The reaction mixture is then warmed to 90 °C, where it is stirred for about 16 hours. After this time the reaction mixture is poured into water. The resultant precipitate is collected by filtration and dried, yielding 2,4-diamino-5-methyl-6-(2,3dihydro-2,2-dimethyl-3-benzofuranon-4-yl)quin-azoline.
AP/P/ 9 4 / 0 0 7 9 6
X
NOTE: The methods of A. Suzuki et al. (J. Am. Chem. Soc. 1989, 111, 314 321) and W.C. Shieh et al. (J. Org. Chem. 1992, 57, 379-381) are used to prepare 2,4-0ΐ3Γηΐηο-5-Γηθ!ίιγΙ-6-(2,3<1ϊΙιγ0Γθ-2,2-0ϊΓηβίίιγΙ-35 benzofuranon-4-yl)quinazoline.
AP.00507
Table ..1
Substituted 2.4-Diaminoquinazolines as Insecticides
Where R1, R2, R6 and R7 are hydrogen.
Cmpd, Nq.
H
Cl
F
Br
I
H
H
H
H
H
H
H
H
H
X
H
H
H
H
H
Cl
Cl
NH4+CI complex Br
F
H
H
H
H
H (I)
Ϊ
H
H
H
H
H
H
H
H
H
Cl
Br
F
I
H
H
H
H
H
H
H
H
H
H
H
H
H
H
F
AP/P/ 9 4/ 0 0 7 9 6
Table 1 (Cont'd)
CmDd. No. W X Y z
15 H Cl H Cl
16 H Br H Br
17 F F H H
18 H F F H
19 H H F F
20 Cl Br H H
21 H Cl H Br
22 H Br H Cl
23 Cl CN H H
24 Cl -NH2 H H
25 Cl Br H Br
26 F F F F
27 -CH3 H H H
28 H -CH3 H H
29 H H -CH3 H
30 -CH3 -NO2 H H
31 -CH3 H H -NO2
32 -CH3 -NH2 H H
33 -cf3 H H H
34 H -cf3 H H
35 H H H -cf3
Table UConid)
AP.00507
Cmpd, No, X Ϊ z
36 -OC2H5 H H H
37 -OCH2CF3 H H H
38 H -NH2 H H
39 -N(CH3)2 H H H
<> 40 -CN H H H
© 41 phenyl H H H
42 H phenyl H H
43 H H phenyl H
44 H XU* H H
45 H Xu, H H
46 H (footnote 1) H H
47 Cl phenyl H H
X‘ ί 48 Cl Xie, H H
49 Cl Xlf H H
50 Cl Cl τλ H H
51 Cl Methanol Solvate A H H
AP/r/ 9 4/ 0 0 7 9 6
Table 1 (Cont'd)
Cmpd, No, W Ϊ Z
52 Cl A H H
53 Cl X’ H H
54 Cl 90 H H
55 H Cl H phenyl
56 H phenyl H Cl
57 phenyl H phenyl H
58 H phenyl monohydrate H phenyl
59 Cl phenyl H phenyl
60 -CH3 Ά H H
61 •CH3 Methanol Solvate CH3 • Ah, H H
62 -CH3 Ach, H H
63 -ch3 X ^Xf3 H H
64 ^iCF3 X x0\5F3 H H
AP. Ο Ο 5 Ο 7
Table 1 (Cont'd)
Where R1, R2, R6, R7, Y and Z are hydrogen; W is chloro; and X is OR3
Ci
Cmpd, No.
65 H
66 -CH3
67 -C5H11
68 -C11H23
69 -CH2Si(CH3)3
70 CH,OO
71
72 F
F
73
74 °2Η4Ο>0Ϊ
6 L 0 0 / <7 6 /d/dV
Table 1 (Cont'd)
Where R1, R2, R6 and R7 are hydrogen.
Cmpd, No, X Ϊ Z
75 H H H
76 s,0,xc: H H H
77 SCH'xc H H H
78 H H H
79 H H H
80 H -st&: H H
81 H H H
82 H u; H H
83 H H H
84 cis isomer H H H
85 πχϊ trans isomer H H H
86 SXO H H H
87 H H H
Table 1 (Cont'd)
Cmpd, No,
W
H
H
H
AP. Ο Ο 5 Ο 7
-s
-S(O)
Ϊ
H
H
H z
H
H
H
Where R1, R2, R6, R7, Y, and Z are hydrogen; and X is
CmDd. No. W QI21 n m B4
91 Cl -N=CH- 1 0 H
92 Cl -CH2NH- 1 Hemimethanol 0 H
93 -CH3 -CH2NH- 1 0 H
94 H -CH2NH- 1 2-HCI 1 H
95 H -CH2NH- 1 1 -C2H5
96 H -CH2NH- 2 2-HCI 1 H
97 H -CH2NH- 2 1 -C2H5
98 H -CH2NH- 3 2-HCI 1 H
99 H -CH2NH- 3 1 -C2H5
AP/P/ 94/00796
6s
Table 1 (Cont’d)
Cmpd, nq, w Ω n m B4
100 Cl -CH2NH- 2 1 -C2H5
101 -CH3 -CH2NH- 2 2-HCI 1 H
102 -ch3 -CH2NH- 2 1 -C2H5
,<··
Where R1, R2, R6 and R7 are hydrogen. Cmod. No W £
103 F H
104 F H
105 H Cl
Y
F
H
H z
H
Cl
F
AP.00507
Table 1 (Cont’d)
Where R1, R2, R®, R7, Y, and Z are hydrogen.
Cmpd. No. W X
106 H Cl xi
107 H ch3 aCH>
108 H CHj CHj
109 H CFj 'ύ
110 H OCHj
111 H OCHj Ίφ CFj
112 -ch3 phenyl
113 -CH3 Xrcl
114 -CH3 Xk
115 -ch3
AP/P/ 9 4/ 0 0 7 9 6
Table 1 (Cont’d)
Cmpd, No, W X
116 -ch3 V Cl
117 -ch3 xx:
118 -ch3 cc,
119 -ch3
120 -ch3 XXc.
121 -ch3 OCH3 Cl
122 -ch3 XxCHl
123 -ch3 ch3 ch3
124 -ch3
125 -ch3 XX‘
126 -ch3 xx(
127 -ch3 xxc
Table 1 (Cont'd'
AP.00507
C.mcd,.NQ w X
128 -CH3 X^zX^OC2H5 V
129 -ch3 V
130 -CH3 Ό-οο,Η,
131 -CH3 X_^X_,CH2OCH3 v
132 -CH3 XT’
133 -CH3 ΤΓ
134 -CH3 χΓ
135 -CH3 Χζ^0(Ο)ΝΗ2
136 -ch3 XiZX^NHC(O)C3H7 V
137 -CH3 XQ^NHS(O)2CH3
138 -CH3 Xr10
139 -ch3 -CHjCHj υ
140 -CH3 -ch2ch2_z^_cf3 V
AP/P/ 9 4 / 0 0 7 9 6
Table 1 (Cont’d)
Cmpd, No
141
-CH3
Where R1, R2, R6, R7, Y and Z are hydrogen; W is methyl; and X is
Cmpd. No Y2 W2 2C Y2 zz
142 H H H H H
143 H H -CF3 H H
144 H -cf3 H -cf3 H
Where R1, R2, R6, R7, Y and Z are hydrogen.
145 -ch3
146 -ch3
147 -ch3 Λ^-οκ,
148 -cf3 XT
Table 1 (Cont'd)
AP. Ο Ο 5 Ο 7
Where R1, R2, R6, R7, Y, and Z are hydrogen; W is methyl; and X is:
Cmpd. No. y: VL X r ZL
149 H H H H H
150 Cl H H H H
151 H Cl H H H
152 H Cl H Cl H
153 H Cl Cl H H
154 H H ci H H
155 -cf3 H H H H
156 H -cf3 H H H
157 H -cf3 H -cf3 H
158 H H -cf3 H H
159 H -CO2CH3 H H H
160 F H H H H
161 H H -CO2CH3 H H
AP/P/ 9 4/ 0 0 7 9 6
Table 1 (Cont’d)
Cmpd, No, XL w: x: r £
162 H F H H H
163 H -CN H H H
164 H F H F H
165 H H -CN H H
166 H H F H H
167 F H F H F
168 H XX H H H
169 H XX H H H
170 H XX, H H H
171 H H XX H H
172 H H XX, H H
173 H H XX, H H
Table 1 (Cont’d)
AP . Ο Ο 5 Ο 7
Where R1, R2,R6, R7, Y, and Z are hydrogen
Cmpd, No, W y: YE £ r z:
174 H H H Cl Cl H
175 Cl H H Cl Cl H
Where R1, R2, r6, r7, γ and Z are hydrogen: and W is methyl
CmDd. No.
176 V COOH
177 v0Fs COjCH3
178 v F
179 XT ethanesulfonic acid salt
180 ΧΓΗ
181 V
AP/P/ 9 4 / 0 0 7 9 6
Table 1 (Cont'd)
Where R1, R2, R6, R7, Y and Z are hydrogen; W is methyl; and X is
Cmod, No V2
182 H
W2
-CF3
Ϊ2
H
Where R1, R2, R6, R7, Y and Z are hydrogen, and W is methyl
Cmpd. No,
183
X
ethanesulfonic acid salt
184
185
SOjC^
186
AP.00507
Table 1 (Cont'd)
Cmpd, No,
187
188 o
189
190
191 och3 a
AP/P/ 94/00796
ci
Table 1 (Cont’d)
AP . 0 0 5 0 7
Table 1 (Cont'd)
Cmpd, No,
197
198
199
X
200
AP/P/ 94/00796
201
Table 1 (Cont'd)
208 o
-CH, 'CHa
AP . Ο Ο 5 Ο 7
IablS-UCpnTd)
Cmpd, No,
209
210
211
212
o
AP/P/ 9 4 / 0 0 7 9 6
Where R1, R2, R®, R7, and Z are hydrogen, W is methyl, and Y is fluoro
Cmpd, No.
213
214
Table 1 (Cont'd)
Where R1, R6, Y and Z are hydrogen, and W is methyl
CmpdJlL R2 q7
215
216
C(CHj)3
CiCH;j)3
217
I A ' OC(CH3)3 '
OC(CH3)3
Where R1, R2, R6, R7, Y and Z are hydrogen, and W is 1-methylethyl [i.e., -CH(CH3)2]
AP .0 0 5 0 7
Table 1 (Cont'd)
Where R1, R2 *, R6, R7, Y and Z are hydrogen r
i
Cmpd, No, W
220 H
221 F
222 F
X
FOOTNOTES 1)ln Compound 46, X is
-CH2N(CH3)
O COOH o
II I II
C-NH-CHCH2CH2-C-OH 2hn Compounds 91-102, the left hand portion of the moiety Q, is attached to the quinazoline ring.
AP/P/ 9 4 / 0 0 7 9 6
Table 1-.3
Melting Points and Empirical Formulas of Compounds of Table 1
COMPOUND MELTING POINT (°C) EMPIRICAL FORMULA
1 240-246 C8H8N4
2 186-188 C8H7CIN4
3 249-251 C8H7FN4
4 202-204 C8H7BrN4
5 192-193 C8H7IN4
6 264-270 C8H7CIN4
7 >360 C8H11CI2N5
8 264-266 C8H7BrN4
9 315-320 C8H7FN4
10 246-247 C8H7CIN4
11 255-256 CeH7BrN4
12 274-277 C8H7FN4
13 266-267 C8H7IN4
14 285-287 C8H7FN4
15 >320 C8H6CI2N4
16 >256 CeH6Br2N4
17 256-257 C8H6F2N4
18 172-173 C8H6F2N4
19 295-296 C8H6F2N4
20 273-275 C8H6B1CIN4
21 >325 C8H6BrCIN4
22 >325 CeH6BrCIN4
23 287, dec. C9H6CIN5
24 204-205 C8H8CIN5
25 188-198 CeH5Br2CIN4
26 215-220 C8H4F4N4
27 210-212 C9H10N4
28 250-253 C9H10N4
29 226-227 C9H10N4
30 228, dec. C9H9N5O2
31 293, dec. C9H9N5O2
32 219-222 C9H11N5
33 176-178 C9H7F3N4
34 234-236 C9H7F3N4
35 244-246 C9H7F3N4
36 214-216 C10H12N4O
37 245-246 C10H9F3N4O
38 255-258 C8H9N5
40 231-232 C9H7N5
41 249-259 C14H12N4
EMPIRICAL FORMULA
COMPOUND
MELTING POINT (°C)
42 244 partial, 255-257 C14H12N4
43 254-258 C14H-12N4
44 287-290 C18H20N4
45 256-259 CI6H10F6N4
46 208-210, dec. C22H24N6O5
47 248-251 C14H11CIN4
48 256-259 C14H10CI2N4
49 268-280 C14H10CIFN4
50 238-240 C14H9CI3N4
51 245-250 C15H13CI3N4O
52 222-225 C14H9CI2FN4
53 >280 C16H9CIF6N4
54 224-229 C18H13CIN4
55 264-268 C14H11CIN4
56 230-238, dec. C14H11CIN4
57 115-125 C20H16N4
58 250-258, dec. C20H18N4O
59 238-242. dec. C20H15CIN4
60 245-247 C16H16N4
61 251-253 C18H22N4O
62 308-311, dec. C19H22N4
63 222-225 C17H12F6N4
64 187-191 C24H12F12N4
65 C14H10CI2N4O
66 C15H12CI2N4O
67 157-162 C19H20CI2N4O
68 C25H32CI2N4O
69 180-183 C18H29CI2N4O
70 C21H15CI3N4OS1
71 C24H21CI3N4O
72 97-110 C21H11CI2F5N4O
73 112-120 C20H15CI2N5O
74 105-112 C25H24CI2N4O4S
75 232-234 C14H10CIN4O
76 268-270 C14H10CI2N4O2S
77 197-199 C15H12N4S
78 200-205 C15H12N4S
79 178-180 CI6HI6N4
80 232-234 C14H10CI2N4S
81 >250 C14H10CI2N4OS
82 286-289 C14H10CI2N4O2S
83 227-229.5 C20HI8N4
84 223-224 C20H16N4
85 257-258, dec. C20HI6N4
AP/P/ 9 4 / 0 0 7 9 6
COMPOUND MELTING POINT (°C) EMPIRICAL FORMULA
86 218-219.5 C18H14N4S
87 217-219 C18H14N4OS
88 235-237 C18H14N4S
89 312-314 C18H14N4OS
90 300-302 C18H14N4O2S
91 234-235 C18H18CIN5O3
92 115-117 C19H24CIN5O4
93 95-210 C21H29N5O6
94 195, dec. C19H23CI2N5O5
95 147-148.5 C21H25N5O5
96 204 C20H25CIN5O5
97 70-72 C22H27N5O5
98 205, dec. C21H27CI2N5O5
99 120-125 C23H29N5O5
100 190-191 C22H26CIN5O5
101 210, dec. C21H27CI2N5O5
102 169-171 C23H29N5O5
103 223-225 C8H6F2N4
104 265-267 C8H6CIFN4
105 295, dec. C8H6CIFN4
106 240-245 C14H11CIN4
107 277-278 C16H16N4
108 282-285 C18H20N4
109 235-237 C15H11F3N4
110 207 C15H14N4O
111 203-206 C16H13F3N4O
112 >250 C15H14N4
113 225-229 C15H13CIN4
114 >250 C15H13CIN4
115 >250 C15H13FN4
116 >250 C15H12CI2N4
117 >250 C15H12CIFN4
118 >250 C16H16N4
119 >250 C16H16N4
120 >250 C17H18N4
121 239-241 C16HI5CIN4O
122 >250 C17H18N4
123 >250 C18H20N4
124 208-210 C16H13F3N4
125 224-226 C16H13F3N4
126 232-235 C16H13F3N4
127 185-190 C19H13F9N4
128 >250 C17HI8N4O
129 >250 C18H20N4O
AP . 0 0 5 0 7
COMPOUND MELTING POINT (°C1 EMPIRICAL FORMULA
130 >250 C18H20N4O
131 238-244 C17H18N4O
132 >250 CI6H13F3N4O
133 265-270 C16H13N5
134 >250 C15H13N5O2
135 279-283 C16H15N5O
136 >250 C19H21N5O
137 274-275 C16H17N5O2S
138 263-268 C21H18N4
139 197-201 C17H18N4
140 209-212 C18H17F3N4
141 122-123 C19H16F6N4
142 >300 C17H15CIN4
143 >300 C18H14CIF3N4
144 >350 C19H13CIF6N4
145 293-295 C13H12N4S
146 270-272 C13H11CIN4S
147 258-260 C14H14N4S
148 202-204 C16H10F6N4
149 C15H12N4O
150 C15H11CIN4O
151 C15HI1CIN4O
152 C15H10CI2N4O
153 C15H10CI2N4O
154 C15H11CIN4O
155 C16H11.F3N4O
156 C16H11F3N4O
157 C17H10F6N4O
158 C16H11F3N4O
159 C17H14N4O3
160 C15H11FN4O
161 C17H14N4O3
162 C15H11FN4O
163 C15H11FN4O
164 C15H10F2N4O
165 C15H11FN4O
166 C15H11FN4O
167 C15H9F3N4O
168 C21H15FN4O
169 C21H15CIN4O
170 C22H15F3N4O
171 C21H15FN4O
172 C21H15CIN4O
173 C22H15F3N4O
6 L 0 0 / V 6 ,'d/dV
Θ4
COMPOUND MELTING POINT (°C) EMPIRICAL FORMULA
174 238-240, dec. C16H13CI2N5O
175 248-250, dec. CI6H12CI3N5O
176 C17H13F3N4O2
177 C18H15F3N4O2
178 CI5H12F2N4
179 315-320, dec. C18H19F3N4O3S
180 257-262 C16H16N4S
181 248 C17H18N4S
182 325-330 C18H14CIF3N4
183 314-320, Dec. C17H19CIN4O3S
184 279 C17H18N4O2S
185 188-192 C19H22N4S
186 235-237 C19H22N4O2S
187 252-254 C16H15CIN4O
188 225-226 C16H12F4N4
189 >350 C17H13F3N4O
190 245-248 C21H18N4
191 C21H17CIN4
192 >250 C21H16F2N4
193 >250 C21H16F2N4
194 C22H17F3N4
195 >230 C21H17CIN4
196 C21H17FN4
197 195-199 C22H17F3N4
198 197-200 C21H16CIFN4
199 198-200 C21H16F2N4
200 C22H20N4
201 260 C22H19CIN4
202 257 C22H19FN4
203 C22H19F3N4
204 217 C21H18N4O
205 202 C21H17CIN4O
206 209 C21H17FN4O
207 217-218 C21H16F2N4O
208 240-244 C19H20N4O
209 207-210 C19H20N4O
210 257-263 C19H19CIN4O
211 259-262 C19H19CIN4O
212 C19H18N4O2
213 242-246 C15H11F3N4
214 224-225 C17H11F7N4
215 Oil C21H16F6N4O2
216 225-226 C27H28F6N4O2
217 >250 C27H28F6N4O4
AP. Ο Ο 5 Ο 7
COMPOUND MELTING POINT (°C) EMPIRICAL-FORMULA
218 251-252 C17H16F2N4
219 212-214 C19H16F6N4
220 C23H23N5OS
221 C16H14FN5O2
222 C17H16FN5O2
(Ο σ>
Ο ο
<□>
£Χ
CL <
κ.
»
Insecticide Formulations
In the normal use of the insecticidal quinazolines of the present invention, they usually will not be employed free from admixture or dilution, but ordinarily will be used in a suitable formulated composition compatible with the method of application and comprising an insecticidally effective amount of the quinazoline. The quinazolines of this invention, like most pesticidal agents, may be blended with the agriculturally acceptable surface-active agents and carriers normally employed for facilitating the dispersion of active ingredients, recognizing the accepted fact that the
0 formulation and mode of application of an insecticide may affect the activity of the material. The present quinazolines may be applied, for example, as sprays, dusts, or granules to the area where pest control is desired, the type of application varying of course with the pest and the environment. Thus, the quinazolines of this invention may be formulated as granules of
5 large particle size, as powdery dusts, as wettable powders, as emulsifiable concentrates, as solutions, and the like. It will be understood that the insecticides themselves may be present as essentially pure compounds, or as mixtures of these quinazoline compounds.
Granules may comprise porous or nonporous particles, such as
0 attapulgite clay or sand, for example, which serve as carriers for the _ quinazolines. The granule particles are relatively large, a diameter of ’· about 400-2500 microns typically. The particles are either impregnated with the quinazoline from solution or coated with the quinazoline, adhesive sometimes being employed. Granules generally contain 0.05-10%,
5 preferably 0.5-5%, active ingredient as the insecticidally effective amount.
Dusts are admixtures of the quinazolines with finely divided solids such as talc, attapulgite clay, kieselguhr, pyrophyllite, chalk, diatomaceous earths, calcium phosphates, calcium and magnesium carbonates, sulfur, flours, and other organic and inorganic solids which acts carriers for the
0 insecticide. These finely divided solids have an average particle size of less than about 50 microns. A typical dust formulation useful for controlling insects contains 1 part of 2,4-diamino-5-methyl-6-[3,5-di(trifluoromethyl)phenyl]quinazoline (Compound 63) and 99 parts of talc.
The quinazolines of the present invention may be made into liquid 3 5 concentrates by dissolution or emulsification in suitable liquids and into solid concentrates by admixture with talc, clays, and other known solid
AP .0 0 5 0 7 carriers used in the pesticide art. The concentrates are compositions containing, as an insecticidally effective amount, about 5-50% quinazoline, and 95-50% inert material, which includes surface-active dispersing, emulsifying, and wetting agents, but even higher concentrations of active ingredient may be employed experimentally. The concentrates are diluted with water or other liquids for practical application as sprays, or with additional solid carrier for use as dusts.
By way of illustration, compound 63 was formulated as a 10% wettable 10 powder (10% WP) as follows:
COMPONENT AMOUNT (Wt/Wt)
Compound 63 10.1%
Wetting Agent 5.0%
Dispersing Agent 3.8%
Wetting/Dispersing Agent 0.9%
Diluent 80.2%
Manufacturing concentrates are useful for shipping low melting products of this invention. Such concentrates are prepared by melting the
5 low melting solid products together with one percent or more of a solvent to produce a concentrate which does not solidify on cooling to the freezing point of the pure product or below.
Useful liquid concentrates include the emulsifiable concentrates, which are homogeneous liquid or paste compositions readily dispersed in
0 water or other liquid earners. They may consist entirely of the quinazolines with a liquid or solid emulsifying agent, or they may also contain a liquid carrier such as xylene, heavy aromatic naphthas, isophorone and other relatively non-volatile organic solvents. For application, these concentrates are dispersed in water or other liquid carriers and normally applied as
5 sprays to areas to be treated.
Typical surface-active wetting, dispersing, and emulsifying agents used in pesticidal formulations include, for example, the alkyl and alkylaryl sulfonates and sulfates and their sodium salts, including fatty methyl taurides; alkylaryl polyether alcohols; sulfates of higher alcohols; polyvinyl
0 alcohols; polyethylene oxides; sulfonated animal and vegetable oils;
sulfonated petroleum oils; fatty acid esters of polyhydric alcohols and the
AP/P/ 9 4/ 0 0 7 9 6 ethylene oxide addition products of such esters: and the addition products of long-chain mercaptans and ethylene oxide. Many other types of useful surface-active agents are available in commerce. The surface-active agent, when used, normally comprises about 1-15% by weight of the insecticidal composition.
Other useful formulations include simple solutions of the active ingredient in a solvent in which it is completely soluble at the desired concentrations, such as acetone or other organic solvents.
As shown in the biological test methods below, the compounds of the present invention were tested in the laboratory as dimethylsulfoxide solutions incorporated into an artificial insect diet or as aqueous acetone or methanol solutions containing a small amount of octylphenoxypolyethoxyethanol surfactant for use as foliar sprays. An insecticidally effective amount of quinazoline in an insecticidal composition diluted for application is normally in the range of about 0.001% to about 8% by weight. Many variations of spraying and dusting compositions known in the art may be used by substituting the quinazoline of this invention into compositions known or apparent in the art.
The insecticidal compositions of this invention may be formulated with other active ingredients, including other insecticides, nematicides, acaricides, fungicides, plant growth regulators, fertilizers, etc.
In using the compositions to control insects, it is only necessary that an insecticidally effective amount of quinazoline be applied to the locus where control is desired. Such locus may, e.g., be the insects themselves, plants upon which the insects feed, or the insect habitat. When the locus is the soil, e.g., soil in which agricultural crops are or will be planted, the active compound may be applied to and optionally incorporated into the soil. For most applications, an insecticidally effective amount will be about 75 to 4000 g per hectare, preferably 150 g to 3000 g per hectare.
Biological Data
The substituted 2,4-diaminoquinazolines of the present invention were incorporated into an artificial diet for evaluation of insecticidal activity against the tobacco budworm (Heliothis virescens [Fabricius]).
Stock solutions of test chemical in dimethylsulfoxide were prepared for each rate of application. The rates of application, expressed as the
AP . 0 0 5 0 7 negative log of the molar concentration, and the corresponding concentrations of the stock solution prepared for each rate are shown below:
Stock Solution
Rate of Application micromolar 4
5
0.5 6
0.05 7
0.005 8
One hundred microliters of each of the stock solutions was manually stirred into 50 mL of a molten (65-70 °C) wheat germ-based artificial diet. The 50 mL of molten diet containing the test chemical was poured evenly into twenty wells in the outer four rows of a twenty-five well, five row plastic tray. Each well in the tray was about 1 cm in depth, with an opening of 3 cm by 4 cm at the lip. Molten diet containing only dimethylsulfoxide at the levels used in the test chemical-treated diet was poured into the five wells in the
0 third row of the tray. Each tray therefore contained one test chemical at a single rate of application, together with an untreated control.
Single second instar tobacco budworm larvae were placed in each well. The larvae were selected at a stage of growth at which they uniformly weigh about 5 mg each. Upon completion of infestation, a sheet of clear
5 plastic was heat-sealed over the top of the tray using a common household flat iron. The trays were held at 25 °C at 60% relative humidity for five days in a growth chamber. Lighting was set at 14 hours of light and 10 hours of darkness.
After the 5-day exposure period, mortality counts were taken, and
0 the surviving insects were weighed. From the weights of the surviving insects that fed on the treated diet as compared to those insects that fed on the untreated diet, the percent growth inhibition caused by each test chemical was determined. From these data, the negative log of the concentration of the test chemical that provided 50% growth inhibition
5 (PI50) was determined by linear regression, when possible, for each test chemical. Where possible, the negative log of the concentration of the test chemical that provided 50% mortality (PLC50) was also determined.
6 L 0 0 / *r 6 /d/dV (
C 25
Generally, the compounds of the present invention inhibited the growth of tobacco budworm. Amongst the most efficacious compounds were Compounds 51 -53, 61, 63, 66, 113, 115-117, 125, 128, 129, 143, and 178-182 with pl50 values of greater than 6.3. Compounds 53, 63, and 129, were highly active compounds with pl50 values of greater than 6.7. All of the compounds exemplified above caused some insect mortality in this test. These data are presented in Table 2.
Certain substituted-2,4-diaminoquinazoline derivatives with high plgO values from the diet test were tested for insecticidal activity in foliar evaluations against the tobacco budworm, beet armyworm (Spodoptera exigua Hubnerj), and the cabbage looper (Trichoptusia ni [Hubnerj).
In these tests against the tobacco budworm and the beet armyworm, nine-day-old chick pea plants (Cicer arietinum) were sprayed at 20 psi to runoff on both upper and lower leaf surfaces with solutions of test chemical to provide application rates as high as 1000 ppm of test chemical. The solvent used to prepare the solutions of test chemical was 10% acetone or methanol (v/v) and 0.1% of the surfactant octylphenoxypolyethoxyethanol in distilled water. Four replicates, each containing four chick pea plants, for each rate of application of test chemical were sprayed. The treated plants were transferred to a hood where they were kept until the spray had dried.
The four chick pea plants in each replicate treated with test chemical as described above were removed from their pots by cutting the stems just above the soil line. The excised leaves and stems from the four plants in each replicate were placed in individual 8-ounce paper cups, which contained a moistened filter paper. Five second-instar (4-5 days old) tobacco budworms or beet armywomns were counted into each cup, taking care not to cause injury. An opaque plastic lid was placed on each cup, which was then held in a growth chamber for a 96 hour exposure period at 25°C and 50% relative humidity. At the end of the 96 hour exposure period the cups were opened, and the numbers of dead and live insects were counted. Moribund larvae which were disoriented or unable to crawl normally were counted as dead. Using the insect counts, the efficacy of the test chemical was expressed in percent mortality. The condition of the test plants was also observed for phytotoxicity and for reduction of feeding damage as compared to an untreated control. Where applicable,
AP·00507
1 computer-generated LC50 values were determined from the percentages of insect mortality.
Foliar tests with cabbage looper were conducted in the same manner as described above, the difference being that pinto bean plants (Phaseolus vulgaris) were used.
Of the compounds evaluated on foliage for insecticidal activity, the more active ones included Compounds 63, 116, and 143 of Table 1. Of these, Compound 143 was one of the most effective, providing excellent mortality of all three insect species in the foliar tests.
0 It will also be noted that certain of the 2,4-diaminoquinazolines are very active in the Diet Test against tobacco budworm, and in the Foliar Test against tobacco budworm, cabbage looper, and beet armyworm. Thus, compounds 185, 186, 188, 190-196, 198, 199, 202, 204-211, 213-215,
217,. 218, and 219 all have plso values of 6.1 or higher in the Diet Test.
σ>
r**
-4“
Ο.
w-Q.
Iabls_2
Insecticidal Activity of Substituted-2,4-diaminoquinazolines Incorporated into the Diet of Tobacco Budworm
Cmpd. No. Rate of ADDlication1 Percent Growth Inhibition2·3·4 Cl505 Percent Mortality6 pLCso7
2 8 ND <4.0 0 .—.
7 ND 0
6 -20 0
5 -11 0
4 33 20
3 4 7 .... 0 —-
4 5 13 .... 0
5 5 -14 <4.0 0
8 4 21 <4.0 0
9 4 5 0
10 4 1 .... 0
11 4 -3 .... 0
12 4 -12 0 . ·—
13 4 -4 0
14 4 -18 0
16 4 5 0
17 4 -15 0
19 4 -8 —- 0
20 7 ND 4.5 0 ....
6 9 0
5 15 0
4 84 15
21 4 23 <4.0 0
22 4 -2 .... 0
AP. Ο Ο 5 Ο 7
Table 2 (Cont'd'
Rate of Percent Growth Percent
Cmod. No. Aoplication1 Inhibition2·3·4 Cl505 Mortality6 uL£so7
25 7 ND .... 0 ----
6 ND 0
5 7 0
4 12 0
26 4 17 o
27 5 14 .... o
4 20 0
28 4 12 o
29 4 -7 o
30 4 42 <4.0 o
31 4 8 o
33 4 13 o
34 4 31 <4.0 o
36 4 7 o
37 4 23 <4.0 o
38 4 -4 o
39 4 TRACE o
40 4 9 o
41 4 4 o
42 6 -4 .... o
5 10 0
4 17 0
45 6 -2 4.9 o
5 56 0
4 82 0
AP/P/ 9 4 / 0 0 7 9 6
Table 2 (Cont’d)
Cmpd. No. Rate of Application1 Percent Growth Inhibition2·3·4 Cl505 Percent Mortality6
46 5 4 4.4 0
4 82 0
47 7 20 5.0 0
6 15 0
5 54 0
4 84 0
48 8 20 6.3 0
7 26 0
6 63 10
5 93 50
4 100 85
49 7 -6 6.1 0
6 63 5
5 98 45
4 97 60
50 7 -5 5.3 0
6 23 0
5 68 10
4 93 40
8 1 5.8 0
7 0 0
6 47 0
5 83 20
4 92 30
51 7 7 6.5 0
6 88 20
5 99 90
4 100 95
8 5 6.8 0
7 25 0
6 87 35
5 97 65
4 99 85
fiLC507
4.5 <4.0 <4.0
5.6
5.4
AP . Ο Ο 5 Ο 7
Table 2-iCflnttU
Cmpd, No. Rate of Application1 Percent Growth Inhibition2·3·4 also5 Percent Mortality6 aLCso7
52 7 -8 6.4 0 <4.0
6 93 10
5 95 25
4 97 45
7 32 6.7 0 5.8
6 93 30
5 100 95
4 100 95
53 7 46 6.9 10 5.6
6 90 25
5 100 95
4 100 95
54 7 9 6.1 0 <4.0
6 64 5
5 94 25
4 96 35
55 4 21 <4.0 0
56 4 6 0
58 4 16 0
59 4 24 <4.0 0
60 7 7 6.1 0 4.6
6 63 5
5 95 25
4 99 75
61 8 9 6.7 0 <4.0
7 49 0
6 78 5
5 92 10
4 96 35
AP/P/ 9 4 / 0 0 7 9 6
Table 2 (Cont’d)
Cmpd, No. Rate of Application1 Percent Growth Inhibition23,4 Cl505 Percent Mortality6 CL£507
61 8 -6 6.5 0 4.0
(cont.) 7 36 0
6 79 15
5 96 20
4 99 50
62 5 32 4.2 0
4 54 0
63 7 5 5.9 0
6 41 0
5 86 0
4 96 15
7 81 >7.0 55 >7.0
6 94 60
5 100 95
4 100 95
64 6 -2 4.8 0
5 34 0
4 93 0
65 5 6 0
4 3 5
66 7 36 6.7 0
6 82 0
5 92 0
4 97 20
8 2 6.5 0 <4.0
7 19 0
6 84 0
5 94 0
4 98 35
8 7 6.7 0 <4.0
7 24 0
6 83 0
5 94 5
4 99 45
Tab.le-2IC.QDtd)
AP.00507
Cmpd. Bq. Rate of Application1 Percent Growth Inhibition2·3·4 plso5 Percent Mortality6 pLCso7
67 6 16 5.0 0 ....
5 46 0
4 86 10
68 6 0 5.0 0 <4.0
5 53 0
4 94 35
6 3 4.9 0 <4.0
5 44 0
4 94 25
69 6 34 5.2 0
5 50 0
4 86 5
70 6 15 5.5 0 4.3
5 85 0
4 99 75
71 6 -8 4.7 0 —«
5 48 0
4 70 0
6 5 4.3 0
5 9 0
4 65 0
72 6 1 5.1 0
5 72 0
4 95 25
73 6 58 0
5 89 5
4 95 10
7 7 6.1 0
6 71 0
5 91 0
AP/P/ 9 4 / 0 0 7 9 6 f '
Table 2 (Confd)
Cmpd, No. Rate of Application1 Percent Growth Inhibition2·3·4 Cl505 Percent Mortality6
73 (cont) 4 94 15
74 7 3 5.0 0
6 6 0
5 59 0
4 87 5
75 5 14 <4.0 0
4 34 0
76 4 16 —- 0
77 6 3 4.4 0
5 13 0
4 75 30
78 6 27 4.6 0
5 33 0
4 63 0
79 5 14 4.1 0
4 56 0
80 5 30 4.7 0
4 89 20
81 6 -7 4.7 0
5 28 0
4 91 20
82 8 23 5.8 5
7 15 0
6 28 0
5 84 40
4 97 95
7 12 5.5 0
6 11 0
5 87 5
CLQ507 <4.0
4.9
4.0
AP . Ο Ο 5 Ο 7
Table 2 (Cont'd)
CffiPCLfcifi· Rate of Application1 Percent Growth Inhibition23·4 Pl505 Percent Mortality6 oLCso7
82 (cont.) 4 97 50
83 6 9 4.7 o
5 25 0
4 77 5
84 6 19 4.3 0
5 20 0
4 56 5
85 4 -6 0
86 6 16 <4.0 0
5 15 0
4 30 0
87 4 -6 0
88 6 -28 4.8 0
5 47 0
4 88 15
6 15 5.0 0
5 46 &
4 85 10
89 6 19 5.0 0
5 49 0
4 87 0
90 7 23 5.3 o
6 26 0
5 69 0
4 84 10
91 6 39 4.7 o
5 36 0
4 88 10
92 7 14 5.8 o —
6 27 0
5 82 0
6 Ζ Ο Ο / Μ /d/dV
- 100
Table 2 (Cont’d)
Rate of Cmpd, Nq. Application1 Percent Growth Inhibition2·34 Pl505 Percent Mortality6 cLCso7
92 (cont.) 4 93 15
93 6 3 4.8 0
5 39 5
4 85 10
94 4 2 .... 0
95 4 13 .... 0
96 4 -3 0
97 4 29 <4.0 0
98 4 7 .... o
99 4 -7 0
100 5 -6 <4.0 0
4 33 0
101 4 17 o
102 4 14 0 v.....
106 5 -1 4.3 o
4 71 0
107 6 2 5.0 o
5 57 0
4 85 5
108 7 6 4.6 o
6 20 0
5 28 0
4 79 0
109 6 -3 4.7 o
5 68 5
4 92
AP . 0 0 5 0 7
Table 2 (Cont'd)
Rate of Cmpd. No. ADDlication1 Percent Growth Inhibition2·3·4 cl505 Percent Mortality6 pLC.507
110 5 1 <4.0 0
4 43 5
111 5 5 4.3 0
4 68 10
112 6 24 5.6 0 <4.0
5 85 20
4 97 25
113 7 17 6.5 0 5.2
6 86 10
5 98 60
4 98 55
114 6 10 5.2 0 4.2
5 69 25
4 97 55
115 7 28 6.4 0 4.4
6 68 5
5 97 35
4 99 60
116 7 27 6.4 0 5.4
6 65 5
5 99 80
4 100 95
117 7 29 6.4 0 4.5
6 70 0
5 95 20
4 100 75
118 7 23 6.1 0
6 48 0
5 92 0
4 96 15
119 6 10 4.7 0 ....
5 39 0
4 75 15
AP/P/ 9 4 / 0 0 7 9 6
102
Table 2 (Cont’d)
CmDd. No. Rate of Application1 Percent Growth Inhibition23·4 Cl505 Percent Mortality6 BLC507
121 7 6 6.2 0 4.6
6 76 0
5 97 35
4 99 70
122 6 40 5.8 0 ....
5 96 20
4 89 20
123 7 21 6.2 0 <4.0
6 59 0
5 91 5
4 97 40
7 0 6.0 0
6 61 0
5 91 0
4 97 5
124 6 7 0 <4.0
5 96 25
4 97 35
8 -16 6.2 0 4.5
7 21 0
6 62 5
5 92 25
4 99 70
125 8 17 6.9 0 5.5
7 37 0
6 89 10
5 100 85
4 100 90
126 6 -5 5.0 0 ....
5 57 0
4 96 20
ΛΡ . 0 0 5 o 7
103
Table 2 (Cont'd)
Cmpd, n.q. Rate of Application1 Percent Growth Inhibition23·4 Pl505 Percent Mortality6 pLCso7
127 6 69 >6.0 0 <4.0
5 94 20
4 96 40
7 5 6.2 0 4.7
6 77 10
5 96 40
4 99 70
128 7 22 6.6 5 4.6
6 85 15
5 96 25
4 99 70
129 7 44 6.8 0 <4.0
6 76 15
5 97 25
4 98 45
130 5 6 4.4 0 —-
4 76 10
131 7 2 5.9 0 ....
6 54 0
5 85 0
4 94 20
132 7 -8 6.0 0 4.4
6 60 15
5 92 25
4 99 70
133 7 -1 5.8 0 4.0
6 31 5
5 91 20
4 96 50
134 6 13 5.3 0 <4.0
5 78 5
4 98 35
AP/P/ 94/00796
Table 2 (ContcQ
Rate of Percent Growth Percent
CmDd. No. ADolication1 Inhibition2·3·4 Cl505 Mortality*
135 6 -6 4.9 0
5 52 0
4 90 15
136 6 4 4.9 0
5 47 10
4 91 30
137 6 1 4.8 0
5 33 0
4 85 25
139 6 7 4.7 0
5 32 0
4 80 10
140 5 15 4.5 5
4 89 20
141 5 33 4.7 0
4 88 5
142 8 15 6.2 0
7 10 0
6 71 5
5 93 5
4 97 40
143 7 40 6.8 0
6 93 0
5 95 0
4 95 30
144 6 -7 5.1 0
5 75 0
4 94 15
145 6 21 5.3 0
5 70 5
4 94 5
pLCSO7 <4.0 <4.0 <4.0.
<4.0
AP · Ο Ο 5 Ο 7
05
Table 2 (Cont'd)
CmDd. No. Rate of Application1 Percent Growth Inhibition2·3·4 Ul505 Percent Mortality6 BLC507
146 7 0 6.0 0 <4.0
6 60 0
5 89 20
4 97 40
147 6 5 5.2 0
5 77 0
4 91 5
148 6 7 4.9 0
5 43 0
4 84 0
174 5 23 4.6 0
4 85 10
175 6 14 5.0 0 .—
5 53 0
4 80 0
177 8 11 6.7 0
7 45 0
6 76 0
5 91 5
4 96 20
178 7 11 6.4 1 4.3
6 80 15
5 94 25
4 98 60
179 7 -1 6.4 5 5.4
6 85 30
5 98 60
4 100 95
181 8 2 6.5 0 <4.0
7 24 0
6 73 5
5 96 5
4 97 25
AP/P/ 9 4 / 0 0 7 9 6 c>
Table 2 (Cont'd)
CmDd. No. Rate of Application1 Percent Growth Inhibition23·4 Pl505 Percent Mortality6
182 8 11 6.4 0
7 25 0
6 63 0
5 92 0
4 95 5
183 7 31 6.6 0
6 82 15
5 97 35
4 100 85
184 7 -3 5.9 0
6 43 0
5 92 15
4 95 20
185 7 7 6.2 0
6 72 20
5 95 25
4 98 50
186 7 30 6.1 0
6 47 0
5 86 5
4 96 10
? 9 6.1 0
6 65 0
5 92 0
4 96 25
7 14 5.9 0
6 35 0
5 88 10
4 95 15
187 7 0 5.6 0
6 23 0
5 80 10
4 93 10
CLQ507 <4.0
4.9
3.9
AP.00507
107
Table 2 (Cont'd)
Cmpd, No. Rate of Application1 Percent Growth Inhibition2·3·4 Cl505 Percent Mortality6 pLCso7
188 7 49 7.0 0 5.1
6 89 30
4 99 70
189 6 -8 4.5 0 <4.0
5 19 0
4 79 25
190 7 24 6.3 0
6 65 10
5 93 0
4 96 15
191 7 42 6.8 0 <4.0
6 85 10
5 95 10
4 97 40
192 7 15 6.5 5 5.1
6 86 20
5 98 60
4 100 75
193 7 16 6.2 0 <4.0
6 64 0
5 90 20
4 96 30
194 7 19 6.3 0 <4.0
6 76 5
5 92 15
4 97 25
195 7 -3 6.1 0 4.9
6 67 5
5 96 45
4 98 90
AP/P/ 9 4 / 0 0 7 9 6 ’ OS
Table 2 (Cont'd)
Cmpd, No. Rate of Application1 Percent Growth Inhibition2·3·4 Cl505 Percent Mortality6 CLO507
196 7 57 .— 0 4.8
6 90 15
5 95 30
4 100 85
9 1 7.1 0 5.2
8 19 0
7 54 0
6 88 15
5 98 70
4 99 90
197 6 7 5.2 0 <4.0
5 77 10
4 96 30
198 7 -2 6.4 0 5.5
6 92 15
5 100 80
4 100 90
199 8 7 7.1 0 5.1:
7 67 0
6 93 20
5 98 60
4 100 75
200 7 -4 5.3 0
6 26 0
5 64 0
4 88 5
201 7 -6 5.6 0 4.8
6 15 0
5 93 25
4 97 95
202 8 8 6.2 0 4.4
7 18 0
6 66 5
5 95 30
4 97 65
AP. Ο Ο 5 Ο 7
09
Table ZIGont'd)
Cmpd, No. Rate of Application1 Percent Growth Inhibition2'34 P1505 Percent Mortality® Pk£507
203 6 6 4.5 0
5 15 0
4 82 15
204 8 4 6.8 0 4.8
7 34 0
6 84 10
5 98 55
4 98 70
205 7 83 10 -..-
6 97 65
5 100 90
4 100 95
8 12 7.2 0 6.2
7 71 15
6 99 70
5 99 90
4 99 95
206 7 11 6.2 0 <4.0
6 74 10
5 95 15
4 97 25
207 8 8 7.0 0 <4.0
7 52 0
6 92 10
5 96 10
4 96 40
208 7 39 6.8 0 <4.0
6 91 15
5 96 15
4 98 30
209 7 68 .... 0 ....
6 71 0
5 85 10
4 96 20
AP/P/ 9 4 / 0 0 7 9 6
1 ο
Table 2 (Cont’d)
Cmpd, No. Rate of Application1 Percent Growth Inhibition2·34 Ol505 Percent Mortality6
209 (cont.) 9 -1 6.7 0
6 22 0
7 37 0
6 70 0
5 87 0
4 96 5
210 9 -4 7.0 0
8 8 0
7 55 10
6 92 25
5 100 75
4 100 85
211 7 14 6.2 0
6 69 0
5 90 5
4 97 40
213 7 -4 6.4 0
6 80 15
5 97 65
4 100 95
214 8 -3 6.8 0
7 33 0
6 90 25
5 100 95
4 100 100
215 7 2 6.4 0
6 88 25
5 98 50
4 100 80
216 6 -10 4.8 0
5 37 0
4 90 45
GLC507
5.5 <4.0
5.2
5.8
5.1 <4.0
AP.00507
Table 2 (Cont'd)
Cmod. No. Rate of Application1 Percent Growth Inhibition2·3·4 Pl505 Percent Mortality6 PLC507
217 7 1 6.1 0 4.3
6 73 0
5 95 20
4 97 60
218 7 8 6.5 0 5.6
6 87 20
5 100 90
4 100 95
219 7 43 6.9 5 5.9
6 96 45
5 100 90
4 100 95
220 7 -4 5.5 0 4.1
6 24 0
5 76 15
4 97 55
221 4 2 0
222 5 3 4.4 0
4 79 15
FOOTNOTES
1) The rate of application is expressed as the negative log of the molar concentration of the test compound in the diet.
2) Percent growth inhibition is derived from the total weight of insects (IW) at each rate of application in the test relative to the total weight of insects in an untreated control, % Gr. inh. = IW (control) - IWItest) X 100 IW (control)
3) ND = No data
4) A minus % growth inhibition indicates that the insects weighed more at the termination of the test than those in the untreated control.
12
5) pI50 is the negative log of the concentration of the test chemical that provides 50% growth inhibition of the test insects.
6) Percent mortality is derived from the number of dead insects (ID) relative to the total number of insects (Tl) used in the test, % Mortality = Tl - ID x 100 Tl
7) PLC50 is the negative log of the concentration of the test chemical that provides 50% mortality of the test insects.
AP. Ο Ο 5 Ο 7
1 3
Table 3
Insecticidal Activity of 2,4-diaminoquinazolines Applied as Foliar Sprays
Percent Mortality
Cmpd No. Rate of ADDlication (ppm) IfiW BAW CJ_(1
7 300 0
100 0
30 0
10 0
3 0
47 3000 80 100 85
1000 75 70 50
300 16 20 35
100 5 5 30
30 5 0 20
48 300 90 95 32
100 53 74 15
30 6 5 0
10 5 5 0
49 1000 100 100 100
300 100 100 100
100 95 100 100
30 85 35 65
10 32 5 40
50 1000 65 100 100
300 44 95 95
100 16 90 89
30 16 50 5
51 300 100 100 100
100 90 100 68
30 80 95 20
10 47 10 5
52 1000 100 100 100
300 100 100 100
100 95 100 100
30 85 90 95
10 44 20 45
AP/P/ 9 4/ 0 0 7 9 6
14
Table 3 (Cont'd)
Percent Mortality
Cmpd No, Rate of ADDlication (ppm) TBW BAW
53 1000 100 100 85
300 100 100 85
100 95 100 75
30 85 90 35
10 30 30 10
54 1000 100 100 100
300 100 100 95
100 55 90 35
30 32 40 28
10 5 5 11
60 1000 100 100 45
300 100 90 20
100 95 40 5
30 89 5 10
10 24 0 15
61 1000 100 100 65
300 100 100 35
100 100 85 35
30 94 70 5
10 95 10 15
63 3000 100 100 100
1000 100 100 100
300 100 100 95
100 100 95 100
30 95 85 95
66 1000 95 100 100
300 90 100 100
100 90 100 100
30 40 100 74
10 11 40 75
67 3000 17 26 25
1000 5 10 5
300 5 5 0
100 0 0 0
30 5 0 11
AP. 0 0 5 0 7 ! ~
Table 3 (Cont'd)
Percent Mortality
Cmpd No, Rate of Application (ppm) TBW SAW CL<1)
68 3000 0 10 10
1000 0 5 6
300 5 0 0
100 0 0 11
30 0 0 5
69 3000 5 45 25
1000 0 0 11
300 0 0 5
100 0 0 10
30 0 0 0
70 3000 0(11) 0(0) 10(32)
1000 0 (0) 0(5) 15(25)
300 0(10) 0(0) 10(20)
100 0 (0) 0(0) 0(20)
30 5 (0) 0(0) 11 (21)
71 1000 5 0 15
300 0 0 21
100 0 0 10
30 0 0 5
10 5 0 15
72 3000 (70) (¢0)
1000 21 (63) 0 45 (35)
300 6 (5) 0 15(17)
100 5 (0) 0 5(10)
30 0 (0) 0 5(10)
10 0 0 10
73 3000 100 100 95
1000 100 100 75
300 80 90 47
100 47 50 45
30 10 5 26
74 3000 25 16 15
1000 5 0 5
300 0 0 15
100 5 0 15
30 0 0 5.
AP/P; 9 4/ 0 0 7 9 6
16
Table 3 (Cont’d)
Percent Mortality
Cmpd Nq, Rate of Application (ppm) IB& BAW £1.(1)
80 1000 90
300 58
100 0
82 1000 100
300 95
100 90
30 39
10 7
3 0
88 1000 95
300 40
100 5
90 1000 0
300 0(35)
100 0 (0)
30 (0)
10 (0)
3 (0)
92 3000 100 10 58
1000 100 0 37
300 90 0 26
100 30 0 30
30 5 0 11
93 1000 20 0 25
300 0 0 15
100 0 0 16
30 10 0 11
10 0 0 5
107 3000 100 95 100
1000 95 78 79
300 53 21 45
100 5 5 10
30 0 10 5
AP.0 0 5 0 7
1 7
Table 3 (Cont'dl
Percent Mortality
Cmpd Ncl Rate of Application (ppm) IBYY BAW £L<1>
108 3000 53 95 75
1000 17 50 26
300 5 5 10
100 5 0 . 0
30 0 0 5
109 3000 100 83 100
1000 90 59 84
300 84 10 85
100 6 16 35
30 0 0 10
111 3000 56 95 41
1000 20 35 26
300 17 5 5
100 5 0 5
30 0 0 0
112 1000 100 100 95
300 100 5 75
100 78 5 58
30 41 0 20
10 5 0 24
1000 95
300 63
100 30
30 0
10 0
96Z00/V6 /d/dV
Table 3 (Cont'd)
Cmpd No,
113
R
Γ (
114
115 . $ c
116
Percent Mortality
Rate of Application (ppm) IEW BAW clO)
1000 100 100 100
300 100 100 100
100 100 95 94
30 100 29 60
10 80 5 58
100 100 95
30 90 83
10 37 50
3 5 11
1 5 0
3000 100 100 100
1000 100 95 75
300 95 85 90
100 80 10 75
30 5 0 45
1000 100 100 100
300 100 90 85
100 95 22 90
30 89 5 85
10 29 5 25
1000 100
300 95
100 50
30 5
10 0
1000 100 100 100
300 100 100 94
100 95 95 95
30 89 90 65
10 18 28 10
100 100 100 85
30 95 85 63
10 30 20 20
3 5 5 15
1 0 0 15
AP .0 0 5 0 7
1 9
Table 3 (Cont’d)
Percent Mortality
Cmpd N& Rate of Application (ppm) Iffifli BAW 0.0)
117 1000 100 100 100
300 100 100
100 95 95 90
30 75 60 84
10 40 5 58
100 90
30 100
10 100
3 15
1 0
118 1000 100 100 83
300 100 95 89
100 100 35 61
30 40 21 28
10 17 0 6
100 100
30 72
10 21
3 5
1 0
121 1000 100 100 ’90
300 100 100 95
100 82 100 95
30 70 95 90
10 37 15 95
122 1000 100 95 71
300 83 40 44
100 53 10 5
30 16 0 6
10 0 0 0
123 1000 80 90 70
300 89 55 55
100 55 30 30
30 20 5 0
10 5 0 5
AP/P/ 9 4 / 0 0 7 9 6
20
Table 3 (Cont'd)
Percent Mortality
CmDd No. Rate of Application (ppm) IEW BAW £Ld)
124 1000 95 85 100
300 95 37 83
100 74 5 75
30 47 0 25
10 25 0 5
125 100 95 95 100
30 95 55 95
10 37 16 28
3 5 0 5
1 0 5 0
100 100
30 90
10 20
3 5
1 5
126 1000 100 95 90
300 80 79 90
100 16 5 37
30 5 0 10
10 5 0 5
300 100 70 100
100 70 5 85
30 24 0 85
10 11 0 47
3 0 0 20
100 100
30 95
10 72
3 30
1 0
127 1000 85 85 100
300 65 55 65
100 45 10 50
30 5 0 15
10 0 0 0
Table 3 (Cont'd)
Cmpd No,
128
129 r
C 131
132 .· 133
I o
134
135
AP.00507
2 1
Percent Mortality
Rate of App-ltgatjon (ppm.) TBW BAW CLd)
1000 100 100 100
300 100 100 90
100 95 95 65
30 85 47 40
10 40 25 5
1000 100 100 100
300 95 95 95
100 74 50 85
30 25 5 95
10 0 0 35
1000 100 85 95
300 95 75 95
100 95 20 70
30 60 0 40
10 5 0 20
1000 100 100 100
300 100 100 84
100 95 95 95
30 80 25 90
10 25 5 15
1000 100 100 100
300 100 95 100
100 95 80 95
30 78 15 37
10 32 5 5
3000 100 100 100
1000 100 95 95
300 95 44 84
100 63 5 40
30 16 0 5
1000 100 15 35
300 70 0 15
100 15 0 5
30 5 0 5
10 5 10 7
AP/P/ 9 4 / 0 0 7 9 6
122
Table 3 (Cont'd)
Percent Mortality
Cmpd No, Rate of Application (ppm) TBW BAW £L<1)
136 1000 29 0 58
300 10 0 5
100 0 5 15
30 0 5 15
10 0 0 10
137 3000 50 0 42
1000 0 0 20
300 0 0 0
100 0 5 10
30 0 0 10
140 3000 74 58 20
1000 56 15 5
300 5 15 5
100 0 10 0
30 0 0 0
141 3000 16 5 0
1000 10 10 0
300 11 0 0
100 0 0 10
30 0 0 0
142 300 100 70 100
100 70 5 85
30 24 0 85
10 11 0 47
3 0 0 20
100 100
30 95
10 72
3 30
1 0
143 1000 100 100 100
300 100 100 100
100 100 100 89
30 100 100 90
10 44 67 85
AP.00507
123
Table 3 (Coat'd)
Percent Mortality
CmpdNflx Rate of Application (oom) IBW BAW £L<1>
143 (cont.) 100 100 100 95
30 90 95 90
10 85 70 95
3 19 5 45
1 0 0 5
100 100 100
30 95 89
10 79 70
3 10 15
1 0 0
144 3000 11 40 65
1000 10 0 55
300 0 0 5
100 0 0 10
30 0 0 5
146 1000 95 95 90
300 94 70 85
100 90 5 20
30 89 0 5
10 0 0 0
174 3000 5
1000 11
300 5
100 0
30 5
175 1000 89
300 35
100 10
30 5
10 0
177 300 95 100 60
100 80 95 32
30 58 60 45
10 28 5 35
3 5 0 5
AP/P/ 94/00796
124
Table 3 (Coord)
Percent Mortality
Cmpd No. Rate of Application (ppm) IEW BAW £L0)
177 (cont.) 300 100 100 90
100 95 95 95
30 53 90 60
10 21 6 45
3 0 5 10
178 1000 100 100 100
300 100 100 80
100 95 95 79
30 84 63 47
c 10 56 30 50
300 80
100 100 75
30 100 90
10 90 90
3 32 5
1 6
179 100 100 95 100
30 65 63 95
10 53 5 40
3 5 0 10
1 0 0 0
181 1000 100 95 74
300 90 20 75
o 100 79 10 50
30 28 0 5
10 11 0 10
182 1000 100 90 100
300 83 32 95
100 53 5 75
30 35 0 85
10 5 0 37
183 1000 100 100 100
300 100 100 100
100 95 90 100
30 89 55 95
10 53 15 90
Table 3 (Cont'dl c>
AP.0 0 5 0 7
125
Rate of
Application (ppm)
Percent Mortality
Gmcd-No.
TBW fiAW £1.0)
183 (cont.) 100 30 10 3 1 95 84 59 5 0 80 42 45 10 5
184 1000 95 39 79
300 72 5 10
100 45 0 5
30 5 0 0
10 0 0 0
185 1000 100 100 90
300 100 89 80
100 80 55 25
30 11 15 0
10 6 16 5
186 1000 100 75 89
300 72 20 55
100 67 5 11
30 35 0 10
10 5 0 0
188 1000 100 100 100
300 100 100 100
100 100 100 100
30 95 85 84
10 71 65 55
100 100 100 80
30 95 95 58
10 71 37 60
3 6 5 5
1 6 0 0
189 300 5 95 70
100 0 44 20
30 0 5 11
10 11 5 0
3 5 0 10
6 Z 0 0 / 7 6 /d/dV
126
Table 3 (Cont’d)
Rate of
Cmpd No, Application (ppm)
Percent Mortality
IBW £jJ1)
189 (cont.)
3000 84
1000 39
300 10
100 0
30 0
190
191
192
193
1000 100 95 100
300 100 58 70
100 95 5 85
30 50 0 45
10 11 0 5
3000 100 100 100
1000 100 100 100
300 95 100 100
100 100 100 90
30 85 80 85
100 89 95 100
30 67 56 95
10 22 5 20
3 21 0 0
1 0 0 0
300 100 100 100
100 95 95 95
30 30 42 74
10 5 5 40
3 5 0 5
1000 100 100 85
300 90 95 85
100 89 83 85
30 22 90 25
10 0 10 5
1000 100 100 100
300 83 100 100
100 44 100 95
30 5 80 55
10 0 45 15
194
AP . 0 0 5 0 7
127
Table 3 (Cont'd)
Percent Mortality
CmcsLMfix Rate of Application (ppm) BAW £1.(1)
194 (cont.) 300 95 100 100
100 67 100 90
30 10 90 79
10 6 44 20
3 0 5 0
195 1000 95 47 15
300 61 26 20
100 11 15 15
30 0 0 10
10 0 0 5
196 3000 100 100 100
1000 100 100 100
300 100 100 80
100 100 100 65
30 83 53 75
100 95 95 95
30 80 6 35
10 5 5 11
3 0 0 0
1 6 0 5
197 1000 25 5 25
300 5 5 0
100 0 0 0
30 0 0 0
10 0 0 0
700 21 16 60
100 5 5 0
30 0 0 5
10 0 0 0
3 0 5 10
198 300 100 100 65
100 95 100 60
30 53 0 37
10 33 5 5
3 0 0 5
iwr>! 94 / 00796
128
Table 3 (Cont'd)
Cmpd No,
198 (cont.)
199 c
200 c
o
201
202
Percent Mortality
Rate of Application (ppm) TBW BAW clO)
300 95 -
100 68
30 11
10 0
3 7
300 100 100 95
100 100 100 67
30 95 95 58
10 68 25 30
3 6 5 0
3000 95 100 100
1000 79 100 95
300 50 95 79
100 5 68 75
30 0 15 60
1000 100
300 95
100 95
30 80
10 55
100 75
30 75
10 25
3 20
1 15
1000 95 95 55
300 53 45 45
100 5 20 25
30 0 0 5
10 5 11 10
30 6 0 55
3 21 0 5
A λ c Π 1 ftp . υ υ □ υ ι
129
Table 31Cont’d)
Percent Mortality
Cmpd No, Rate of Application (ppm) TfiW z&u CLO)
204 30 65 20 100
3 10 5 25
300 100 100 90
100 94 95 73
30 89 24 85
10 40 26 80
3 5 0 25
205 100 100 95 50
30 100 75 5
10 78 5 0
3 25 0 6
1 18 0 5
300 100 100 95
100 95 100 40
30 90 85 5
10 70 32 5
3 10 5 5
206 1000 100 100 94
300 89 100 85
100 90 100 26
30 53 100 25
10 11 60 35
207 1000 100 100 100
300 100 100 100
100 100 100 100
30 94 100 95
10 63 100 22
100 100 100
30 94 100
10 40 95
3 7 13
1 5 0
AP/P/ 9 4/ 0 0 7 9 6
130
Table 3 (Contd)
Percent Mortality
Cmpd Nq, Rate of Application (ppm) IfiYY BAW clO)
208 1000 100 100 100
300 100 100 100
100 95 100 90
30 80 95 70
10 35 55 80
300 100
100 100 100 100
30 95 79 80
10 59 25 70
3 11 5 5
1 0 5 0
300 100 100
100 100 100 95
30 95 95 65
10 90 45 76
3 19 5 16
1 11 5 10
100 100 95
30 89 80
10 26 85
3 10 5
1 0 0
209 300 95 95 74
100 35 42 25
30 5 5 20
10 0 10 15
3 0 0 15
300 70 79 84
100 16 60 63
30 5 5 10
10 5 16 20
3 0 10 5
300 90 80 85
100 50 53 84
30 16 10 10
10 0 5 5
AP . 0 0 5 0 7
131
Table 3 (Cont'd)
Percent Mortality
Rate of
OmcdlkL AcpiicaliprUcam) IBSfli BAW CLd)
209 (cont.) 3 5 0 0
1 0 5 5
210 100 95 100 84
30 100 100 95
10 50 95 95
3 21 50 70
1 5 5 22
o 100 100 100 95
30 90 100 95
10 71 95 80
3 29 25 80
1 0 5 5
211 30 30 56 80
3 11 5 5
300 95 100 80
100 80 94 80
30 21 78 75
10 5 11 55
3 0 0 10
c 213 300 100 95
V. 100 95 85 35
30 85 30 15
r , 10 6 21 20
3 0 0 5
1000 75
300 47
100 44
30 10
10 5
214 100 95 95 74
30 75 75 68
10 11 10 21
3 0 10 5
1 0 0 5
AP/P/ 9 4 / 0 0 7 9 6
132
Table 3 (Cont'd)
Percent Mortality
Cmpd No, Rate of Application (ppm) IBW BAW CU1)
215 1000 100 100 100
300 100 100 100
100 95 95 90
30 69 65 37
10 7 10 5
216 100 0 26 15
30 0 0 5
10 6 0 5
3 5 11 10
1 0 21 21
217 1000 100 100 84
300 95 95 53
100 69 28 25
30 6 5 0
10 0 0 0
218 300 100 100 100
100 100 100 100
30 95 75 89
10 75 50 95
. 3 33 5 15
• • 219 100 100 100 100
30 100 95 85
10 79 15 79
3 5 5 5
1 5 0 16
1) TBW, BAW, and Cl are, respectively, the above-described tobacco budworm, beet armyworm, and cabbage looper.

Claims (2)

  1. ι . A substituted diaminoquinazoline compound characterized by the formula;
    C 20 wherein
    R1 is hydrogen or lower alkyl;
    R2 is hydrogen, lower alkyl, lower alkylcarbonyl, or lower aikoxycarbonyl; or R1 and R2, taken together, form the group -R6-O-R®, wherein R6 is lower alkylene;
    R® is hydrogen;
    R7 is hydrogen, lower alkylcarbonyl, or lower aikoxycarbonyl;
    W is selected from hydrogen, halogen, lower alkyl, lower haloalkyi, phenyl, and phenyl substituted with lower alkyl or lower haloalkyi, with the proviso that when X is phenyl, W is other than hydrogen;
    Y and Z are selected from hydrogen, halogen, and phenyl; and
    AP/P/ 9 4/ 0 0 7 9 6
    X is selected from (a) phenyl;
    (b) aryl substituted with one or more of halogens, lower alkyl, lower haloalkyi, lower alkoxy, lower alkylthio, lower alkylsulfonyl, formyl, lower aikoxycarbonyl, phenyl or phenyl substituted with one or more halogens or lower haloalkyi, phenoxy or phenoxy substituted with one
    134 or more halogens, lower haloalkoxy, lower alkoxyalkyl, carboxy, cyano, nitro, aminocarbonyl, lower alkylcarbonylamino, lower alkylsulfonylamino;
    or substituted phenyl of the formula
    OR3
    Ci ί
    c.
    (
    c.
    wherein R3 is hydrogen; alkyl; tri(lower alkyl)silylaJkyi; (4-halophenyl)lower alkyl; pentahalophenylalkyl; pyridin-2-ylalkyl; or 2-(4-alkylsulfonylphenoxy)alkyl;
    (c) naphthyl;
    (d) thienyl or thienyl substituted with halogen, lower alkyl, or haloalkyl;
    (e) aroyl, or substituted aroyl of the formula:
    c c
    wherein V’, W’, X’, Y', and Z’ are independently selected from hydrogen, halogen, haloalkyl, cyano, carboxy, lower alkoxycarbonyl, and phenyl substituted with halogen or haloalkyl;
    (f) (aryl)(halo)alkenyl of the formula:
    r
    C
    C 20 c
    AP . 0 0 5 0 7
    135 wherein V”, W”, X, Y”, and Z” are independently selected from hydrogen, halogen, lower alkyl, lower haloalkyl, cyano, carboxy, lower alkoxycarbonyl, and aminocarbonyl;
    (g) 2,3-dihydro-2,2-dimethylbenzofuran-4-yl; 2,3-dihydro-2,2dimethylbenzofuran-7-yl; 6-halo-2,3-dihydro-2,2-dimethylbenzofuran4-yl; 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-yl; or 2,3-dihydro2,2-dimethyl-3-benzofuranon-4-yl.
  2. 2 The compound of claim 23 characterized in that X is phenyl substituted with chloro, trifluoromethyl, or (aryl)(halo)alkenyl compounds of the formula where V”, W”, X”, Y”, and Z” are independently selected from hydrogen, trifluoromethyl, or 2,3-dihydro-2,2-dimethylbenzofuran-4-yl; 2,3-dihydro-2,2dimethylbenzofuran-7-yl; 6-halo-2,3-dihydro-2,2-dimethylbenzofuran-4-yl; 5halo-2,3-dihydro-2,2-dimethylbenzofuran-7-yl; or 2,3-dihydro-2,2-dim,ethyl-3benzofuranon-4-yl.
    3 The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-methyl-6-(3,5-di(trifluoromethyl)phenyl]quinazoline.
    < The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-methyl-6-(3,5-dichlorophenyl)quinazoline.
    5 The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-methyl-6-[1 -chloro-2-(4-trifluoromethylphenyl)ethenyl]-quinazoline.
    θ The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-chloro-6-(5-chloro-2-methoxyphenyl)quinazoline.
    AP/P/ 9 4 / 0 0 7 9 6
    136 ' 7 The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-chloro-6-[5-chloro-2-(pyridin-2 ylmethoxy)phenyl]quinazoiine.
    8 The compound of claim 23 characterized in that the 5 diaminoquinazoline is 2,4-diamino-5-methyl-6-(5-chlorothien-2yl)quinazoline.
    9 The compound of claim 23 characterized in that the diaminoquinazoline is 2,4-diamino-5-methyl-6-(4-trifluoromethylphenylcarbonyl)quinazoline.
APAP/P/1996/000796A 1993-02-18 1996-02-16 Novel insecticidal 2,4-diaminoquinazolines. AP507A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1938993A 1993-02-18 1993-02-18
US14949193A 1993-11-09 1993-11-09

Publications (2)

Publication Number Publication Date
AP9600796A0 AP9600796A0 (en) 1996-04-30
AP507A true AP507A (en) 1996-07-18

Family

ID=26692173

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/1994/000620A AP506A (en) 1993-02-18 1994-02-16 Insecticidal substituted-2,4-diaminoquinazolines.
APAP/P/1996/000796A AP507A (en) 1993-02-18 1996-02-16 Novel insecticidal 2,4-diaminoquinazolines.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
APAP/P/1994/000620A AP506A (en) 1993-02-18 1994-02-16 Insecticidal substituted-2,4-diaminoquinazolines.

Country Status (10)

Country Link
US (3) US5534518A (en)
EP (1) EP0684824A4 (en)
AP (2) AP506A (en)
AU (1) AU6298694A (en)
IL (1) IL108630A0 (en)
MA (1) MA23116A1 (en)
MX (1) MX9401249A (en)
TN (1) TNSN94014A1 (en)
TW (1) TW315298B (en)
WO (1) WO1994018980A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR012634A1 (en) * 1997-05-02 2000-11-08 Sugen Inc QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE
JP4370002B2 (en) * 1997-08-08 2009-11-25 富山化学工業株式会社 Quinolone carboxylic acid derivative or salt thereof
MY122278A (en) * 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US7030109B2 (en) 1999-07-19 2006-04-18 Pharmacia & Upjohn Company 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
BRPI0112121B1 (en) * 2000-06-30 2015-09-01 Basf Ag Process for preparing 4-bromoaniline derivatives
PE20020506A1 (en) * 2000-08-22 2002-07-09 Glaxo Group Ltd PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS
CA2439463A1 (en) * 2001-02-28 2002-09-06 Anders Hallberg Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
DK1474395T3 (en) * 2002-02-12 2008-02-11 Smithkline Beecham Corp Nicotinamide derivatives useful as p38 inhibitors
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
CA2516942A1 (en) * 2003-02-04 2004-08-19 Mcmaster University Use of quinazoline derivatives or other compounds for inhibiting dihydrofolate reduxtase; screening assay for the identification of novel therapeutics and their cellular targets
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
MXPA05011103A (en) * 2003-04-16 2005-12-12 Hoffmann La Roche Quinazoline compounds useful as p38 kinase inhibitors.
US20040248880A1 (en) * 2003-04-25 2004-12-09 Jacobsen Eric Jon 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position
US7465738B2 (en) * 2003-06-16 2008-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as promoters of SMN2
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1765810B1 (en) 2004-06-08 2016-08-17 Families of Spinal Muscular Atrophy 2,4-diaminoquinazolines for the treatment of spinal muscular atrophy
WO2006029385A2 (en) * 2004-09-08 2006-03-16 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
WO2006050843A1 (en) * 2004-11-09 2006-05-18 F. Hoffmann-La Roche Ag Aminoquinazolines compounds
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
CA2659376C (en) 2006-08-01 2014-10-14 Jasbir Singh 2,4-diaminoquinazolines for spinal muscular atrophy
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
MX2010010998A (en) * 2008-04-07 2011-01-25 Chelsea Therapeutics Inc Antifolate compositions.
DE102008022221A1 (en) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitors of human aldosterone synthase CYP11B2
AU2010270596A1 (en) * 2009-07-08 2012-02-02 Chelsea Therapeutics, Inc. Stable crystalline polymorphs of the dipotassium salt of (S) -2- {4- [2- (2, 4-diamino-quinazolin-6-yl) -ethyl] -benzoylamino} -4-methylene-pentanedioic acid
JP2013510163A (en) * 2009-11-06 2013-03-21 チェルシー・セラピューティクス,インコーポレイテッド Enzyme inhibitory compounds
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
WO2012064377A1 (en) * 2010-03-29 2012-05-18 Chelsea Therapeutics, Inc. Antifolate compositions
US8835445B2 (en) 2010-06-02 2014-09-16 Trius Therapeutics, Inc. Dihydrofolate reductase inhibitors
WO2012078708A1 (en) 2010-12-07 2012-06-14 Chelsea Therapeutics, Inc. Combination comprising methotrexate and an antifolate compound
CN102552271B (en) * 2010-12-09 2014-08-06 中国科学院上海药物研究所 Use of quinazoline compounds in preparation of drug for resisting flaviviridae viruses
GB201104153D0 (en) * 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
TW201311149A (en) * 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha Pesticide
SI3321265T1 (en) 2015-03-04 2020-07-31 Gilead Sciences, Inc. 4,6-diamino-pyrido(3,2-d)pyrimidine compounds and their utilisation as modulators of toll-like receptors
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
MA46093A (en) 2016-09-02 2021-05-19 Gilead Sciences Inc TOLL-TYPE RECEIVER MODULATING COMPOUNDS
TW202212339A (en) 2019-04-17 2022-04-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI751516B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202115056A (en) 2019-06-28 2021-04-16 美商基利科學股份有限公司 Processes for preparing toll-like receptor modulator compounds
AU2022425491A1 (en) 2021-12-30 2024-07-04 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028473A1 (en) * 1979-11-01 1981-05-13 Pfizer Inc. Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945859A (en) * 1960-07-19 Diaminoquinazolines and method of
GB1045180A (en) * 1963-09-20 1966-10-12 Parke Davis & Co Quinazoline derivatives
GB1141249A (en) * 1967-05-25 1969-01-29 Parke Davis & Co New quinazoline compounds and methods for their production
GB1161644A (en) * 1967-09-11 1969-08-13 Parke Davis & Co Quinazoline Compounds and process means for producing the same
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3635979A (en) * 1969-09-29 1972-01-18 Pfizer Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines
DE2125907C3 (en) * 1971-05-25 1980-12-18 Bayer Ag, 5090 Leverkusen Azo dyes, processes for their production and processes for dyeing and / or printing fiber materials
JPS53103484A (en) * 1977-02-21 1978-09-08 Takeda Chem Ind Ltd Quinazoline derivatives, process for their preparation and nsecticedes and fungicides
US4377581A (en) * 1980-03-03 1983-03-22 Pfizer Inc. Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
US4298613A (en) * 1980-05-05 1981-11-03 E. I. Du Pont De Nemours And Company Agricultural heterocyclic sulfenamides
FI70411C (en) * 1980-12-29 1986-09-19 Pfizer FORM OF ANTHYPERTENSIVE 4-AMINO-6,7-DIMETOXY-2-PIPERAZINOQUINAZOLE DERIVATIVES
US4451466A (en) * 1982-07-02 1984-05-29 Shell Oil Company Use of pyrroloquinazolinediamines as pesticides
US4672116A (en) * 1985-12-20 1987-06-09 Ortho Pharmaceutical Corporation Substituted 5,6-dialkoxyquinazoline derivatives
US4677219A (en) * 1986-07-17 1987-06-30 Warner-Lambert Company Substituted benzonitriles
US4818753A (en) * 1987-09-18 1989-04-04 Sri International Synthesis and method of use for 2, 4 diaminoquinazoline
US5411963A (en) * 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
IL89027A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
US5141941A (en) * 1988-11-21 1992-08-25 Ube Industries, Ltd. Aralkylamine derivatives, and fungicides containing the same
GB8910722D0 (en) * 1989-05-10 1989-06-28 Smithkline Beckman Intercredit Compounds
JPH0776316B2 (en) * 1989-09-19 1995-08-16 キヤノン株式会社 Recording liquid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028473A1 (en) * 1979-11-01 1981-05-13 Pfizer Inc. Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
TNSN94014A1 (en) 1995-04-25
EP0684824A4 (en) 1996-02-14
US5874579A (en) 1999-02-23
AP9400620A0 (en) 1994-04-30
MX9401249A (en) 1994-08-31
TW315298B (en) 1997-09-11
AU6298694A (en) 1994-09-14
AP9600796A0 (en) 1996-04-30
AP506A (en) 1996-07-18
IL108630A0 (en) 1994-05-30
WO1994018980A1 (en) 1994-09-01
US5616718A (en) 1997-04-01
US5534518A (en) 1996-07-09
MA23116A1 (en) 1994-10-01
EP0684824A1 (en) 1995-12-06

Similar Documents

Publication Publication Date Title
AP507A (en) Novel insecticidal 2,4-diaminoquinazolines.
JP3353895B2 (en) Pest control pyrimidine compounds
EP0238711B1 (en) Thiadiazabicyclononane derivatives, processes for their production and herbizidal compositions
DK165108B (en) 3-Phenyluracils and enol ethers and salts thereof, process for preparing them, weed-killer which comprises these compounds, and the use of the compounds for controlling weeds
JPH0649689B2 (en) 2-anilinopyrimidine derivative, method for producing the compound, and agrochemical composition containing the compound
CZ301369B6 (en) Herbicidally active derivatives of 3-hydroxy-4-aryl-5-oxopyrazoline
JPH07165730A (en) New agricultural chemical
KR0172947B1 (en) Heterocyclic compounds
AU645193B2 (en) Pyridine derivative, production thereof, herbicide and method of weeding
US5532367A (en) Insecticidal pteridines and 8-deazapteridines
JPH08119807A (en) Indoles as insect controller and tick controller
AU673222B2 (en) Insecticidal 5-substituted-2,4-diaminopyrimidine derivatives
EP0046467B1 (en) Quinoxaline derivatives and herbicidal composition
KR100497135B1 (en) Herbicidal 2,6-disubstituted pyridine and 2,4-disubstituted pyrimidine
KR900000566B1 (en) Photoactive azole pesticides
HU217994B (en) Insecticidal and acaricidal (halogenalkylthio/sulfinyl and sulfonyl/)-arylpyrrole derivatives, compositions containing such compounds and use thereof
JPS6033112B2 (en) Diphenyl-substituted pyrazolinones and their production methods and uses
JPS61130275A (en) Pyridazinone derivative, preparation thereof, and insecticidal, miticidal and fungicidal agent
AP36A (en) Pyrazoline insecticides
IL132831A (en) Pesticidal and parasiticidal
JPH09176170A (en) Microbicide
JPH0678339B2 (en) Fused heterocycle derivative
JPH05201808A (en) Nematocide composition
JPH0725857A (en) Condensed heterocyclic derivative and herbicide
JP2530155B2 (en) 2-Phenoxypyrimidine derivative and herbicide